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ABSTRACT
Patent rights are territorial. A patent granted in the United
States is only enforceable in the United States. Yet increasingly so, a
successful launch of new technology or a product requires global
strategy, and global strategy requires global patent protection.
Seeking patent protection in multiple countries is routine for many
companies. And while these multi-national teams of patent counsel
and global administrative support are skilled at navigating different
patentability requirements and processes, they are currently
experiencing a new challenge: defending the priority date of their
original patent application when seeking transnational patent
protection. Companies are facing this challenge because of
differences in patent assignment laws around the world. Patent
assignment laws play a crucial role in patent protection, with the
majority of patentable inventions around the world created by
employees and assigned to employers.
This Article demonstrates the interconnection of patent priority
around the world by showing how the application of different rules
regarding patent assignment law and patent priority currently lead
to higher transaction costs and wasteful, if not abusive, litigation.
This Article proposes two possible solutions to the global problem
of proving patent priority: build a centralized recordation database
modeled after the already-existing secured transactions recordation
systems in place in almost every country worldwide, or,
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alternatively, include a disclosure requirement in the alreadyexisting transnational patenting processes.
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INTRODUCTION
Companies are facing a new challenge: proving the priority of
their employees’ patented inventions in post-grant patent
proceedings. Most often, these companies are large companies that
have a global presence, such as Pfizer (United States), Samsung
(South Korea), Philips (Netherlands), Novartis (Switzerland), BMW
(Germany), and Toyota (Japan). Yet, increasingly, this challenge is
also faced by small to medium size companies that have a
transnational presence, including private biotechnology and
technology firms that commonly consider their patent portfolios as
their most valuable asset.
In 2016, the United States Patent and Trademark Office
(“USPTO”) reported that eighty-five percent of the 151,000 issued
patents were assigned to for-profit companies. 1 This percentage
reflects a slight increase over the last ten years.2 This means that the
majority of patents in the United States rely on patent assignments
to transfer ownership from individual inventors to companies—in
many instances, employee to employer.
So, while patent law scholarship is often dominated by
discussion of the patentability requirements—namely, that an
invention must be subject matter eligible, new, nonobvious, and
sufficiently described,3 meeting these patentability requirements is
1
See NATIONAL SCIENCE FOUNDATION, NATIONAL SCIENCE BOARD, Chapter 8,
Invention: United States and Comparative Global Trends (2018),
https://www.nsf.gov/statistics/2018/nsb20181/report/sections/inventionknowledge-transfer-and-innovation/invention-united-states-and-comparativeglobal-trends [https://perma.cc/QG5J-M5FE] (breaking down the patents issued
by the USPTO to U.S. owners in Appendix Table 8-1). See also Ryan Abbott, I Think,
Therefore I Invent: Creative Computers and the Future of Patent Law, 57 B.C. L. REV. 1079,
1092 (2016) (citing this number and explaining that it is common for scientific and
technical workers to preemptively assign their patent rights to employers as a
condition of employment).
2
See Paul J. LaVanway, Jr., Patent Licensing and Discretion: Reevaluating the
Discretionary Prong of Declaratory Judgment Jurisdiction After Medimmune, 92 MINN.
L. REV. 1966, 1987 (2008) (reflecting similar numbers from the USPTO data).
3 See, e.g., Jeanne C. Fromer, Patent Disclosure, 94 IOWA L. REV. 539 (2009)
(discussing the written description requirement); Jeanne C. Fromer, The Layers of
Obviousness in Patent Law, 22 HARV. J.L. & TECH. 75 (2008) (discussing the
nonobviousness requirement); Mark A. Lemley et al., Life after Bilski, 63 STAN. L.
REV. 1315 (2011) (discussing the subject matter eligibility requirement); Richard L.
Robbins, Subtests of “Nonobviousness”: A Nontechnical Approach to Patent Validity, 112
U. PA. L. REV. 1169 (1964) (discussing the nonobviousness requirement); Sean B.
Seymore, The Teaching Function of Patents, 85 NOTRE DAME L. REV. 621 (2010)
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not enough to compete in a global market. The patent holder must
also have the ability to prove her ownership of the patent, most often
by producing a written patent assignment when challenged. This
ownership has a direct relationship with the priority position of the
patent holder. 4 Focusing on employee inventions, this Article
explains how inventions are assigned differently throughout the
world, creating a lack of transparency and unpredictable results in
litigation. In short, if the effective priority date—the date when the
inventor steps into line compared to others—is changed, the patent
will likely be invalidated.
This is because in patent law, only one patent will be granted per
patentable idea. There is no independent creation defense in patent
law, like there is in copyright law.5 The one idea, one invention rule
is important in patent law. Recently, Professor Lemley has
persuasively argued that much innovation occurs near
simultaneously, with inventors conceiving their groundbreaking
discoveries within just weeks of one another.6 With some form of a
first-to-file priority rule employed throughout the world, inventors
rush to their respective country’s patent office to get the first place
in the priority line before another inventor does the same.
Given the global economy, it is no longer adequate protection in
many instances to obtain patent protection solely in one’s local
country when the patented product or method can easily be
transported, streamed, or otherwise used and shared within seconds
or days to far-reaching places in the world. Obtaining international
protection means that patent holders must prove the priority of their
patent on a global stage. This comes with a unique set of challenges.

(discussing the written description requirement); Sean B. Seymore, Rethinking
Novelty In Patent Law, 60 DUKE L.J. 919 (2011) (discussing the novelty requirement).
4
See 35 U.S.C. § 102 (2012) (outlining the “[c]onditions for patentability;
novelty and loss of right to patent” in the United States); Robert P. Merges, Priority
and Novelty Under the AIA, 27 BERKELEY TECH. L.J. 1023, 1024 (2012) (identifying the
filing of a patent application as the critical date and the relevance of worldwide
prior art).
5
See Fred Fisher, Inc. v. Dillingham, 298 F. 145, 147 (S.D.N.Y. 1924) (citing
Judge Hand’s famous explanation: “One may infringe a patent by the innocent
reproduction of the machine patented, but the law imposes no prohibition upon
those who, without copyright, independently arrive at the precise combination of
words or notes which have been copyrighted.”).
6
See Mark A. Lemley, The Myth of the Sole Inventor, 110 MICH. L. REV. 709, 711
(2012) (providing many examples of the social phenomenon of simultaneous
invention).
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A recent opinion from the District Court in The Hague is
exemplary.7 In this opinion, two U.S. patent applications were filed
naming two employee-inventors as the applicants. These employeeinventors worked for a U.S.-based multinational biotechnology
company. At the time, U.S. patent law required the inventors to be
named as the patent applicants, as opposed to the company that they
worked for named as the inventor. Within the applicable 12-month
period permitted by international law,8 the biotech company filed a
single foreign application through the Patent Cooperation Treaty
(“PCT”) based on the U.S. patents (and claiming their priority date),
naming the biotechnology company as the applicant. For a PCT
application, a company, not an individual inventor, is the
appropriate applicant, although the inventors must still be
identified in the PCT application.
The biotech company was granted a European patent stemming
from the PCT application, which vested in the biotech company and
claimed the priority date of the earlier filed U.S. patent applications.
In a post-grant European opposition challenging the validity of the
European patent, it was argued that the priority claim was
inappropriate due to, in essence, a break in the chain of title. Simply,
the applicants were different from the U.S. patent applications to the
PCT applications. The problem? The biotech company must now
prove that it had a proper assignment of the right to priority from the
two inventors to their employer, the biotech company.
In the United States, the right of priority is not independent from
the right to the patent itself. Accordingly, practitioners do not need
a separate, formal assignment of the right of priority. Elsewhere,
and in much of Europe, this right is separate, and as such, must be
explicitly assigned separate from the patent. Ultimately, despite
each patent application, those in the United States and the PCT
application, effectively and appropriately filed when viewed apart
from one another, the biotech company could not prove that the
right to priority had been properly assigned to it by the time the PCT
application was filed. Consequently, the biotech company’s
7 See Celltrion Inc. v. Biogen Inc. et al., Case No. C/09/519083/ HA ZA 161117, Decision, District Court of the Hague (Sept. 27, 2017) [hereinafter Celltrion
Inc. v. Biogen Inc. et al.], https://uitspraken.rechtspraak.nl/inziendocument?id=
ECLI:NL:RBDHA:2017:11301 [https://perma.cc/66RJ-R95X].
8
See Paris Convention for the Protection of Industrial Property art. 4, Mar. 20,
1883, 21 U.S.T. 1583, 828 U.N.T.S. 305 (According to Article 4 of the Paris
Convention for the Protection of Industrial Property (Paris Convention), there is a
12-month right of priority as of the date of these U.S. patent applications filing).
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European patent was invalidated in the European post-grant
proceeding. Yet, in a different forum, on appeal, the District Court
of The Hague, the exact opposite conclusion was found: the
biotechnology company was permitted to retain the priority date for
the European Patent.
This example is not unique. Defending the priority of a patent
priority should, in theory, come down to a seemingly simple chainof-title analysis. Yet, because the rules of patent assignment laws
vary substantially from country to country, this simple analysis is
quite complicated. Moreover, the vast majority of patentable ideas
and inventions are created by employee-inventors and assigned to
employers, meaning that these differences in patent assignment
laws creates uncertainty, as well as wasteful, inefficient litigation in
post-grant proceedings around the world. Finally, differences in
patent assignment laws result in lost opportunities for cross-border
collaboration.
This Article argues that a centralized recordation database be
created and housed by the World Intellectual Property Organization
(“WIPO”), one that will track the chain of title of international
patents. Alternatively, WIPO, and/or the proposed European
unitary patent system should require a few extra additional
disclosures during the PCT and/or unitary patent filing process to
achieve transparency and predictability.
Part 1 discusses patent priority, including identifying the
significance of priority and novelty, and the recent rise in priority
challenges throughout the world. Part 2 identifies the relevant laws
affecting patent priority for those claiming patent priority from U.S.
applications. Part 3 then identifies the relevant laws affecting patent
priority for those claiming patent priority from countries in Europe,
notably the Netherlands and Germany. These two countries have
routinely seen their patent holders lose patent priority dates, and
both stand at a stark contrast to a common law system like that of
the United States. Part 4 does the same identification for patent
priority stemming from countries in East Asia, including Japan, the
Republic of Korea, and China. Finally, Part 5 provides suggestions
on how to increase the predictability of priority challenges, thereby
decreasing inefficient and burdensome post-grant litigation.

Published by Penn Law: Legal Scholarship Repository,

762
1.

U. Pa. J. Int'l L.

[Vol. 41:3

PATENT PRIORITY & THE RISE IN PRIORITY CHALLENGES IN THE
IP5 OFFICES

This Article will focus on the patent laws within the jurisdictions
of five particular intellectual property offices. The five offices are
the European Patent Office (“EPO”), the Japan Patent Office (“JPO”),
the Korean Intellectual Property Office (“KIPO”), the National
Intellectual Property Administration of the People’s Republic of
China (“CNIPA”), and the United States Patent and Trademark
Office (“USPTO”).
These five intellectual property offices comprise the “IP5.” The
IP5 is a cooperation between the five largest intellectual property
offices in the world. Together, these five offices “handle about 80
percent of the world’s patent applications, and 95 percent of all work
carried out under the Patent Cooperation Treaty (“PCT”).”9
Recognizing the opportunity for natural synergies with this high
volume of patenting, during the first ten years of the IP5 Offices cooperation, the IP5 Offices directed their efforts at “improv[ing] the
efficiency of the examination process for patents worldwide.” 10
Over the course of the past decade, the IP5 Offices have
commissioned many studies to assess the evolving global need of its
users. As a result, a new vision of the IP5 Offices was published in
2017: “Patent harmonization of practices and procedures, enhanced
work-sharing, high-quality and timely search and examination
results, and seamless access to patent information to promote an
efficient, cost-effective and user-friendly international patent
landscape.”11
The IP5 is so exciting precisely because of the recognition of the
evolving needs of innovators throughout the world. Global
collaboration and coordination are made more possible when the
five largest players act together in their combined users’ interests.
One of the first projects the IP5 Offices undertook was to build a
catalogue for its users displaying the areas in which patent practices
9
About IP5 co-operation, FIVE IP OFFICES, https://www.fiveipoffices.org/
about.html [https://perma.cc/2J26-QBQH] (last visited Feb. 22, 2019).
10 Id. See also Areas of Activity, FIVE IP OFFICES, https://www.fiveipoffices.org/
activities.html [https://perma.cc/5L66-KAUT] (last visited Feb. 22, 2019)
(Moreover, “[t]he vision of the IP5 Offices is global co-operation, which has been
defined as ‘the elimination of unnecessary duplication of work among the IP5
Offices, the enhancement of patent examination efficiency and quality of guarantee
of the stability of the patent right.’”).
11
About IP5 co-operation, supra note 9.
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differed between the five offices.12 Two areas in this catalogue that
received special attention: priority and novelty.13
The determination of which inventor receives the sole patent is
governed by the so-called “priority rule.” The priority rule tackles
the “compared to whom” question. 14 Yet the determination of
whether the inventor gets to claim its invention is the first of its kind
is governed by the novelty patentability requirement. The novelty
patentability requirement tackles the “compared to what”
question.15
Starting with the priority rule, there are two general options: the
“first-to-invent” rule and the “first-to-file” rule. Most basically,
should the patent claimant who was first in time to invent receive the
patent or, instead, should the patent claimant who was the first to
file a patent application receive the patent? The first-to-invent
priority rule was a longstanding hallmark of the U.S. patent
system.16 Yet when President Obama signed the America Invents
Act (“AIA”) into law, U.S. patent law moved towards a first-to-file
rule. Most simply, if there is a priority dispute regarding a patent
filed on or after March 16, 2013, in the United States, the dispute is
most often settled by determining which inventor was the first to file
its respective patent application.17
When the United States adopted the first-to-file priority rule,
there was hope that there would be meaningful international patent
harmonization. Yet the United States “did not in fact adopt the
12
See Catalogue of Remaining Differences, FIVE IP OFFICES (2012),
https://www.fiveipoffices.org/wcm/connect/fiveipoffices/f52e30ce-ac79-4a23bfca-b370df61683d/catalogue_of_differing_practices_2012_update.pdf?
MOD=AJPERES&CVID= [https://perma.cc/JAE3-YTMR] (last visited Feb. 22,
2019) (listing the categories of differing practice between IP5 offices).
13
See
IP5
Statistics
Report,
FIVE
IP
OFFICES
(2014),
http://www.fiveipoffices.org/statisticsreports/2014edition/ip5sr2014.pdf
[https://perma.cc/6XY7-35E2] (last visited Feb. 22, 2019) (explaining that
“Priority” is a term of art, and yet it is not defined consistently throughout the
worldwide patent laws).
14 See Merges, supra note 4, at 1028 (“Strictly speaking, priority is a question of
who, as between two rival inventors, will obtain a patent for an identical invention . . . .
Novelty is a question of whether, as between an inventor and a piece of prior art, the
inventor acts before or after the prior art enters the field.”).
15 See id. (“if an inventor can show that he or she did whatever is required
before a reference enters the prior art, the inventor gets the patent.”).
16
See David S. Abrams & R. Polk Wagner, Poisoning the Next Apple? The
America Invents Act and Individual Inventors, 65 STAN. L. REV. 517, 520 (2013) (defining
the first-to-invent rule as granting patent priority to “the party that had the
inventive idea first”).
17 Id. at 519.
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[first-to-file priority] rule in the way that the international
community understands the first-to-file rule.”18 The international
community, including the other IP5 Offices, follows what is
commonly termed the “absolute” novelty rule. An absolute novelty
rule is just as it sounds: it follows a “pure first to file system,”
meaning “that if there is a use, sale or publication of information
relating to the invention prior to the filing of a patent application[,]
no patent can be obtained.”19
Instead of the absolute novelty rule, the rule the United States
adopted permits an inventor to prove priority in two ways other
than the earliest filing date: “(1) where the first filer learned of or
outright stole the invention from another person; and (2) where the
second filer made a public disclosure of the invention before the first
filer filed a patent application.” 20 Accordingly, the United States
adopted a first-proven-inventor-to-file rule, where an inventor
proves her priority either by filing a patent application to reserve
her place in line at the USPTO, or by making a widely available
disclosure.21
This means that unlike the first-to-invent priority rule that places
the highest value on the first conception of the new invention, the
first-to-file priority rule in the United States most values the first
public disclosure of the new invention. This disclosure may be
either making a widely available disclosure, such as through a
printed publication, or by simply filing a patent application. In the
United States, these events start the twenty-year clock that runs
before the invention goes into the public domain.
While the United States and other countries mostly agree now
on the priority rule to use when determining the priority date of any
given invention, the international community does not agree on the
level of novelty.22 A novelty dispute concerns one inventor and her
18 Karen E. Sandrik, A Uniform Grace Period: Promoting International Research
and Development Collaboration, 91 TUL. L. REV. 99, 104 (2016).
19
Gene Quinn, Patentability: The Novelty Requirement of 35 U.S.C. 102,
IPWATCHDOG (June 10, 2017), http://www.ipwatchdog.com/2017/06/10/patent
ability-novelty-requirement-102/id=84321/ [https://perma.cc/CXB3-82N5].
20 Merges, supra note 4, at 1028.
21 See, e.g., Merges, supra note 4, at 1046 (“While the AIA moves the United
States to a first-inventor-to-file system, it does not go all the way to complete
international harmonization.”).
22
For an example of the varying language used regarding this topic, see Gene
Quinn, Harmonization and the Quest for an Elusive International Grace Period,
IPWATCHDOG (Feb. 10, 2015), https://www.ipwatchdog.com/2015/02/10/
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claimed invention compared to the already existing references
composing the relevant prior art.23 What constitutes prior art is a
difficult question to answer, especially when comparing the answer
to other answers to this question around the world. In the United
States, the basic novelty rule requires that an inventor’s claimed
invention is new compared to all previously granted patents,
published patent applications, and printed applications across the
world. 24 The claimed invention must also be new compared to
inventions anywhere in the world that are already in the public’s
use, already on sale, or otherwise available to the public.25
In regards to the specific timing of the comparison between the
claimed invention and the prior art, the Patent Act defines the
“effective date” as the filing date of a patent application.26 While it
is no longer possible to antedate, or back-date, a patent application
under current patent law, “the effective filing date of a claimed
invention is [still] determined on a claim-by-claim basis and not an
application-by-application basis.” 27 This is because claims may
have different geneses, such as the actual filing date of the patentat-issue in the United States versus a right to priority of a patent
application filed in a foreign country.28
While the novelty rule is not central to this Article, it is important
to realize the impact the priority date has on the novelty of an
invention. If, due to a successful priority challenge, the effective
date is pushed back one year or even just a few months, there will
harmonization-and-the-quest-for-an-elusive-international-grace-period/
id=54599/ [https://perma.cc/DA2Y-YTZD] (discussing the “grace period”).
23 See Merges, supra note 4, at 1030 (explaining the general rule of novelty and
its exceptions “to the general rule that, to be valid, an application has to be filed
before a prior art event”).
24 (a) NOVELTY; PRIOR ART.—A person shall be entitled to a patent
unless—(1) the claimed invention was patented, described in a printed
publication, or in public use, on sale, or otherwise available to the public
before the effective filing date of the claimed invention; or (2) the claimed
invention was described in a patent issued [to another] or in [another’s]
application for patent [that is] published [and that] . . . was effectively filed
before the effective filing date of the claimed invention.
See 35 U.S.C. § 102(a) (2012).
25 35 U.S.C. § 102(a) (2012).
26 35 U.S.C. § 101(b) (2018).
27
Manual of Patent Examining Procedure, U.S. Patent and Trade Office,
2152.01 (last revised Jan. 2018) [hereinafter MPEP], https://mpep.uspto.gov/
RDMS/MPEP/e8r9#/current/ch2100_d20033_1afb3_e6.html
[https://perma.cc/EFA5-XGRW].
28 See 35 U.S.C. § 119 (2018).
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almost certainly be new prior art references that will serve to destroy
the once-thought novelty of the at-issue invention. Overall, if a
patent holder cannot defend the priority date of the original patent
application, the patent holder will either lose out to a competing
patent application with the superior claim to the invention, or the
patent holder may very well lose her ability to claim her invention
is new and/or nonobvious.
The following two subparts will show the rise in priority
challenges of post-grant patents in Europe, and then briefly explain
the basics of the relevant post-grant patent opposition and
invalidation systems of the IP5 Offices.
1.1. The Sudden Rise in Priority Challenges
In the past 15 years, there has been an explosion in post-grant
patent priority challenges. Although the rise in priority challenges
is most visible in Europe, the potential for these type of priority
challenges also exists in the United States, Japan, and the Republic
of Korea (“Korea”), among other countries outside of the IP5
Offices.29
Extrapolating from recent case law, it appears that patent
challengers may have learned about challenging chain-of-title on the
grounds that there should be a separate and express assignment of
the right of priority from a 2006 European Opposition opinion.30 In
that opinion, the board held that the patent holder, GE Plastics Japan
K.K., had not carried its burden to prove that its priority date,
claiming priority from a Japanese patent application, was valid.31
The problem is that the applicant for the Japanese patent application
was GE Plastics Japan K.K., whereas the applicant for the European
Patent was General Electric Company. 32 Subsequently, and
presumably not until the potential chain of title problem was noticed
See infra Parts 2-4.
GE Plastics Japan K.K. v. Koninklijke DSM N.V., No. T 0062/05, Decision,
Bd. of App. of the Eur. Patent Office (Nov. 14, 2006).
31 See id. at 24 (“The Board, after deliberation, informed the Parties, that the
priority claim could not be considered as valid . . . .”).
32 See id. at 10 (“There was a lack of identity of the proprietor of the priority
right based on JP 2498697 and the proprietor of the contested patent . . . ”). See also
id. at 28 (identifying the issue that “priority is claimed . . . by different persons as
can be seen from the European patent application (i.e. General Electric Company)
and the priority document (i.e. Nihon GE Plastics K.K.)”).
29
30
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nearly seven years after the filing date of the European Patent
application, General Electric transferred the at-issue right of
priority, as well as the European Patent, to GE Plastics Japan K.K.
This assignment was not within the twelve-month priority window,
and the assignment could not retroactively overcome the chain-oftitle issue presented by the two different applicants.
The patent holder, GE Plastics Japan K.K., did present evidence
that GE Plastics Japan K.K. had assigned the patent application to
General Electric Company, but it could not present evidence that it
had expressly assigned the right of priority. It attempted to make
the argument that it, in essence, would be “illogical for GE Plastics
Japan to assign the application to [the parent company,] General
Electric Company[,] without assigning the corresponding priority
rights,”33 yet the board was unconvinced.
Instead, the board seemed to focus on the idea that “[p]riority
rights are assignable independently of the corresponding patent
application . . . .” 34 And although the board explained that “the
European Patent Convention (“EPC”) does not contain any
regulations concerning the formal requirements that an assignment
of priority rights for the filing of an European patent application
should fulfill in order to be considered valid,” the board also found
that because the priority date on a patent has a “crucial effect,” the
transfer of priority rights should, “in the Board’s view, be proven in
a formal way.”35 The board found support in a different part of the
EPC, Article 72, which requires that the assignment of an European
Patent application be in writing and “signed by or on behalf of the
Parties to the transaction.”36
Overall, GE Plastics K.K. could not meet this formal requirement
of a written and independent assignment. As a result, it lost its
priority date. 37 As mentioned above, the consequence of losing
one’s priority date is twofold: one, there is the potential that another
inventor is now ahead in the so-called priority line for the one
patent; and two, the invention is no longer new, now failing to meet
the novelty requirement. Either way, the effect is devastating to the
patent holder: the patent, in effect, loses its monetary value, if it is
affirmed at all (as opposed to invalidated altogether).
33
34
35
36
37

Id. at 23.
Id. at 29.
Id.
Id. at 30.
Id. at 32.
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Showing the downstream impact of this 2006 opinion is a more
recent opinion. This 2015 opinion demonstrates some of the
development in the approximately ten years since the
groundbreaking 2006 opinion.
In the 2015 opinion, Teva Pharmaceutical Industries Ltd. had a
post-grant patent challenged by multiple competitors in a European
Opposition.38 Teva’s patent, European Patent No ‘489, was issued
from a patent application that was filed through what is sometimes
termed an international application or a PCT application, 39 on
August 23, 2005. This international application claimed priority
from two U.S. provisional applications, with the earliest priority
date of August 23, 2004.40
In the European Opposition, the patent challengers argued that
Article 87 of the European Patent Convention “require[s] a separate
and express assignment of the right of priority executed by the
applicants of the provisional US applications,” the ones upon which
priority for EP ‘489 is based.41 While the statute does not explicitly
state an assignment of the right of priority must be done in a
separate and express assignment, Article 87 does provide that
applicants, or “his successors in title, shall, enjoy, for the purpose of
filing a European patent application in respect of the same
invention, a right of priority during a period of twelve months from
the date of filing of the first application.42
38
Teva Pharmaceutical Indus. Ltd v. Hexal AG, No. T 0205/14, Decision, Bd.
of App. of the Eur. Patent Office (June 18, 2015). Ultimately, Teva’s patent was
invalidated due to lack of inventive step, the United States equivalent of nonobviousness. See also id. at 50-66.
39
The Patent Cooperation Treaty (“PCT”) is a World Intellectual Property
Organization (“WIPO”) system that:
[A]ssists applicants assists applicants in seeking patent protection
internationally for their inventions, helps patent Offices with their patent
granting decisions, and facilitates public access to a wealth of technical
information relating to those inventions. By filing one international patent
application under the PCT, applicants can simultaneously seek protection for
an invention in a very large number of countries.”
PCT—The International Patent System, WORLD INTELLECTUAL PROPERTY
ORGANIZATION (WIPO), http://www.wipo.int/pct/en/ [https://perma.cc/DVL4WL4Q] (last visited Feb. 23, 2019).
40 See Teva, supra note 38, at 1.
41 See Teva, supra note 38, at 6.
42
European Patent Convention art. 87(1) Convention art., Oct. 5, 1973, 1065
U.N.T.S 199 [hereinafter EPC], [https://perma.cc/K7ER-74V3].
Article 87
expressly refers to the Paris Convention for the Protection of Industrial Property
(Paris Convention), which has very similar language to Article 87. Article 4 of the
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The board started its discussion with Article 87(1), the same
article at issue in the 2006 decision, stating that:
[T]he right to claim priority for a European patent
application from the filing date of . . . [a] previous
application . . . originates in the applicant of said first
application. Therefore, in principle, the applicant has to be
the same for the first application and for the subsequent
applicant for which the right of priority is invoked.43
The board then noted that a successor in title is also able under
the statute to claim the right of priority.44 As to the right of priority
itself, the board explained that the right of priority is “an
independent right up and until it is invoked for one or more later
applications to which it becomes an accessory.”45 Yet even so, this
board disagreed that the independence, the severability of the right
to priority, must be likewise assigned in a “separate and express
assignment.”46 This stands in sharp contrast to the holding from the
2006 European Opposition opinion. Here, the board decided that
because Article 87(1) was silent as to formalities, that this silence was
not an invitation to read any such formalities into it. As such, “the
present board cannot follow [the 2006 board’s] reasoning.”47
When determining which law to apply in regard to the right of
priority assignment to a successor in title, this board stated that
Article 72 is distinct from Article 87. Article 72 represents a
collective law that specifically overrules national law, “which, in
general, governs legal acts related to property interests in such
applications[.]”48 After further discussion, this board decided that
the silence of Article 87 should be construed as carrying with it no
Paris Convention provides for an international right of priority, lasting 12 months
as of the date of filing of a patent application for filing in other countries. Just as
with EPC Article 87, this right is conferred to “any person who has duly filed an
application for patent . . . in one of the countries of the Union, or his successor in
title.” Paris Convention for the Protection of Industrial Property, as last revised at
the Stockholm Revision Conference, Mar. 20, 1883. 21 U.S.T. 1583, 828 U.N.T.S. 305,
supra note 8.
43 Teva, supra note 38, at 24.
44 Teva, supra note 38, at 24 (“the right of priority may also be invoked by the
‘successor in title’ of the person who has filed the first application . . . it is
recognised that the right of priority . . . may be transferred from the original
applicant to a third person.”).
45 Teva, supra note 38, at 24
46 Teva, supra note 38, at 25.
47 Teva, supra note 38, at 26-27.
48 Teva, supra note 38, at 27-28.
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formal requirements, and that because the EPC provisions do not
directly answer questions of this type of assignment, the validity of
transfer of a priority right “is a matter of national law.”49
As a result, parties before the Boards of Appeals of the EPO, and
first the Opposition Division, must navigate not only the intricacies
of patentability requirements, but also which law, and what formal
requirements, are going to be imposed upon any successor in title.
Assigning patents from the original inventor(s) to another, a
successor in title, is an everyday practice for companies such as
General Electric and Teva Pharmaceuticals. On the one hand,
requiring those companies to understand and navigate specialized
rules is fair. On the other hand, when all companies, both large and
small, have a shifting target as to what law applies, with some not
permitted to obtain written patent assignments at early stages due
to national patent law, it becomes an impossible task of navigation.
1.2. Challenging Post-Grant Patents in the IP5 Offices
Since the 1970s, the EPO has provided a way for petitioners to
challenge issued patents in post-grant opposition proceedings.50 As
such, the EPO is the experienced leader of the other IP5 Offices. That
said, there is change coming to Europe with the likelihood that a
Unified Patent Court (“UPC”) will be introduced sometime soon,
change that may shake up this previously consistent stability that is
so attractive to patent applicants and patent challengers. 51 The
Teva, supra note 38, at 30 (citing references omitted).
See, e.g., Olga Partington & Paul Calvo, On the Attack, EUR.
BIOPHARMACEUTICAL REV. 66, 68 (2015) (describing the European post-grant
opposition proceedings as more favorable to challengers than American
proceedings because of the few substantive requirements placed on challengers
during EPO proceedings); Filip De Corte, Anthony C. Tridico, Tom Irving, Stacy D.
Lewis & Christina N. Gervasi, AIA Post-Grant Review and European Oppositions: Will
They Work in Tandem, or Rather Pass Like Ships in the Night?, 14 N.C. J.L. & TECH 93,
98-99 (2012) [hereinafter AIA Post-Grant Review] (“Oppositions allow third parties
(other than the applicant and the EPO) to bring forward facts and arguments that
are prejudicial to the patentability of the invention that is claimed in the opposed
patent.”).
51
For the most recent status of the Unified Patent Court (UPC), see Agreement
on a Unified Patent Court, 2013 O.J. (C 175) 1. Most notably, Germany has yet to
ratify the agreement that would establish the UPC and a unitary patent. Id. The
EPO is currently stating on its website that “[t]he start of the new system is currently
expected for the first half of 2019.” When Will the Unitary Patent System Start?
49
50
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United States, with the AIA, only recently adopted a robust postgrant opposition system, one that is similar to the EPO post-grant
opposition. In 2015, just a few years after the AIA, Japan
reintroduced its previously terminated post-grant opposition
system. Similarly, Korea just reintroduced its previously terminated
system in 2017. And although China does not currently have a postgrant opposition system, the CNIPA, like the other IP5 Offices, does
have the traditional litigation-based invalidation option to challenge
patents after they are granted.
This subpart will briefly give the highlights of each system to
impart a basic understanding of how priority dates of previously
filed patents are most often being challenged. If the reader is already
familiar with post-grant oppositions in the IP5 Offices, please
proceed to Part 2.
Starting with the post-grant opposition system in Europe,
European oppositions must be filed within nine months of patent
issuance. 52 Assuming a petitioner pays the appropriate fees and
follows other basic filing procedures, anyone can file a petition
against as many patent claims as the petitioner can support. 53
Perhaps to increase the motivation to challenge potentially dubious
or weak patents, the petitioner does not have to reveal the real party
behind the petition. 54 This is commonly called the “straw man”
opposition,55 which thereby permits potential competitors to shield
EUROPEAN PATENT OFFICE, https://www.epo.org/law-practice/unitary/unitarypatent/start.html [https://perma.cc/7AQX-8K5N] (last visited Feb. 23, 2019).
52 Chapter 5: The European patent grant procedure. EUROPEAN PATENT GUIDE 59
(19th ed. 2019), http://documents.epo.org/projects/babylon/eponet.nsf/
0/8266ED0366190630C12575E10051F40E/$File/how_to_get_a_european_patent_
2019_en.pdf [https://perma.cc/ZAZ4-8JWS].
53 EPC, supra note 42, at art. 99(1):
Within nine months of the publication of the mention of the grant of the
European patent in the European Patent Bulletin, any person may give notice
to the European Patent Office of opposition to that patent, in accordance with
the Implementing Regulations. Notice of opposition shall not be deemed to
have been filed until the opposition fee has been paid.
54 See Michael J. Flibbert, Leythem A. Wall, & Maureen D. Queler, Coordinating
European and U.S. Post-Grant Patent Opposition, FINNEGAN (Nov. 4, 2014),
https://finnegan.com/en/insights/coordinating-european-and-u-s-post-grantpatent-opposition.html
[https://perma.cc/FG37-TSXA]
(explaining
how
petitioners may use the “straw man” provision” to file under the name of a different
party and conceal their identities).
55
STERNE, KESSLER, GOLDSTEIN & FOX, P.L.L.C., EUROPEAN PATENT OFFICE (eds.
Jason D. Eisenburg & Robert Greene Sterne) 1 PATENT OFFICE LITIGATION § 23:5
Westlaw (database updated Jan. 2017) [hereinafter PATENT OFFICE LITIGATION] (“If
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their identity. This is particularly useful if the petitioner is a licensee
of the patent or a direct competitor of the patent holder.
A filed opposition may challenge the subject matter of the
European patent, the written description of the European patent, or
that the subject matter of the European patent is broader than the
application itself, whereby the patent “extends beyond the content
of the application as filed[.]”56 This means that if the priority date of
the patent is incorrect due to a break in the chain-of-title, the change
of a priority date will almost always likewise impact the written
description and enablement of the patent. Thus, grounds for
opposition necessarily also include a challenge that the priority date
of the patent is incorrect, as demonstrated by the EPO decisions
above. For a discussion of this very point, the following is
illustrative:
[I]f the appellant’s right to priority is denied, that could only
be for subject matter disclosed in the earlier UK application.
That application disclosed only the embodiments using a
self-closing slit valve in a dome-shaped region whereas the
subsequent UK application contains both the dome-shaped
and the flat end embodiment. Thus[,] the only subject matter
which could lose priority is the dome-shaped region subject
matter, because Article 87(4) EPC cannot apply to the
alternative flat end subject matter[,] which was not in the
earlier application[,] but only in the subsequent UK
application. Hence, for the flat end embodiment the priority
date of 7 April 1992 must be valid.57
In terms of filing fees, the European opposition process is
affordable, with an official fee around $1,000 U.S. that is
independent of how many claims are challenged or grounds for
such challenges are asserted. 58 The petitioner may challenge a
European patent on a number of grounds, including:
the opponent does not wish to identify themselves (possibly because of a
commercial interest) it is permitted for another person to file the opposition on their
behalf—this is known as a ‘straw man’ opposition.”).
56
EPC, supra note 42, at art. 100.
57
Decision of the Technical Board of Appeal 3.2.2, T 1056/01, BOARDS OF
APPEAL OF THE EUROPEAN PATENT OFFICE,
5
(June
4,
2003),
https://www.epo.org/law-practice/case-law-appeals/recent/t011056eu1.html
[https://perma.cc/9QV4-W9HM].
58
See Schedule of Fees, EUROPEAN PATENT OFFICE, https://my.epoline.org/
portal/classic/epoline.Scheduleoffees [https://perma.cc/N6FN-FUEW] (last
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[1] that the subject-matter of the patent is not patentable
within the terms of Articles 52-57 EPC, [2] that the invention
is not disclosed clearly and completely enough for a person
skilled in the art to carry it out, [and 3] that the patent’s
subject-matter extends beyond the content of the application
as filed.59
Upon this reexamination of the European patent, the opposition
may be rejected (and the patent validity is, in essence, affirmed), the
patent is amended with a new patent specification, or the patent is
revoked.60
The timeline of the post-grant process from start to finish is
generally within an eighteen to thirty-month turnaround, with
many oral decisions granted in a fifteen to twenty-four-month
timeline.61 As a result, European oppositions are a cost-effective and
time-efficient mechanism for centrally challenging a European
patent.
Conversations in the United States leading up to the AIA
included discussion of international harmonization, including the
adoption of a first-to-file priority rule and also the introduction of a
post-grant opposition proceeding similar to that of the EPO
described above. 62 Arguably trying to achieve this stated policy
visited Mar. 5, 2018) (listing the possible fees associated with the EPO application
process).
59
Oppositions, EUROPEAN PATENT OFFICE, https://www.epo.org/applying/
european/oppositions.html [https://perma.cc/8Y72-X6ML] (last visited Feb. 20,
2019).
60 Id.
61 See Flibbert, Wall, & Queler, supra note 54.
62 See, e.g., 157 CONG. REC. 4369, 4428 (statement of Rep. Manzullo) (“This bill
would finalize the shift towards a European-style patent system through changing
from a ‘first-to-invent’ to ‘first-to-file’ system; establishing a new set of ‘prior use’
rights; and adopting a third European style ‘post-grant’ challenge.”). Prior to the
implementation of the AIA, post-grant ex parte reexamination and inter partes
reexamination proceedings were available. See 35 U.S.C. § 305 (2012) (describing
the process of reexamination proceedings). This pre-AIA system fell short of an
ideal reexamination process. Criticism of pre-AIA post-grant proceedings included
charges of insufficient third-party involvement, unfair bias favoring the patent
holder, and lack of international harmonization of post-grant proceedings. See
Jeffrey P. Kushan, The Fruits of the Convoluted Road to Patent Reform: The New
Invalidity Proceedings of the Patent and Trademark Office, 30 YALE L. & POL’Y REV. 385,
391 (2012) (regarding criticism of unfair bias favoring the patent holder and the lack
of international harmonization of post-grant proceedings); Christopher L. Logan,
Patent Reform 2005: HR 2795 and the Road to Post-Grant Oppositions, 74 UKMC L. REV.
975, 988-89 (2006) (explaining failures in the pre-AIA system, including insufficient
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aim, the AIA introduced significant changes to the U.S. post-grant
opposition system. This included the introduction of post-grant
review (“PGR”), inter partes review (“IPR”), and covered business
method review (“CBM”). After issuance of a patent, PGR is initially
the only adversarial proceeding available to challenge the validity
of the patent within the USPTO. As in Europe, and the other
countries housing the four other IP5 patent offices, there is always
the traditional option of litigation (through district court litigation
in the United States) to challenge an issued patent.
Available grounds for challenging the patent through PGR
include the following patentability requirements: subject-matter
eligibility, novelty, nonobviousness, and the written description.63
Not just anyone can file a PGR petition: those who have already or
are currently in the process of challenging the validity of the same
patent in a U.S. patent infringement lawsuit may not use the PGR
process offered in the United States.64
Notably, unlike that of the European opposition, the U.S. PGR
requires that the real party behind the petition be revealed to the
public.65 Yet like a European opposition, the PGR petition must be
filed within nine months of the patent grant.66 A PGR petition is
submitted to the newly created PTAB, which is staffed by
administrative patent judges, many of whom are experienced patent
prosecutors and, or, patent litigators.67 Although PGRs are similar
to European opposition proceedings, they are not as popular. 68
third-party involvement and the estoppel provision). Although Congress initially
looked to the example of European opposition proceedings, much changed during
the course of legislation. Today, there are still arguments to be made that the United
States’ system is disappointingly distinct from that of the European Patent Office.
See Karen E. Sandrik, The Post-Grant Life: Coordinating & Strategizing Challenges of
Issued Patents in Multiple Continents, 17 CHI. -KENT. J. INTELL. PROP. 449, 450-51 (2018)
(arguing the lack of international harmonization creates opportunities for
inefficient strategic behaviors).
63 See 35 U.S.C. § 321(b) (2012).
64 See id. at § 325(a)(1).
65 Id. at § 322(b).
66 Id. at § 321(c).
67 See Michael Wagner, An Introduction to Administrative Patent Judges at the
Patent
Trial
and
Appeal
Board,
FED.
LAW.
36
(May
2015),
http://www.fedbar.org/Resources_1/Federal-Lawyer-Magazine/2015/May/
Features/An-Introduction-to-Administrative-Patent-Judges-at-the-Patent-Trialand-Appeal-Board.aspx?FT=.pdf [https://perma.cc/4LMN-DQQ2].
68
Jeffrey A. Miller, Katie J.L. Scott, & Bonnie Phan, Post-Grant Review: A
Promising New Tool for Invalidating Patents?, ARNOLD & PORTER (Jan. 18, 2017),
https://www.arnoldporter.com/en/perspectives/publications/2017/01/postgrant-review-a-promising [https://perma.cc/Z9PG-49FB].
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Presumably, one reason is the expense associated with a PGR.
Unlike the low filing fee of the European opposition proceedings,
the minimum filing fee of a PGR is $38,000 U.S., which covers
patents with up to twenty claims. 69 There are additional fees for
every claim over twenty that is challenged.70
After the nine-month PGR period has expired, or after the
termination of any PGR that has been instituted as to the at-issue
patent, an IPR or CBM petition may be filed. Unlike in PGR or in a
European opposition, an IPR petition may only challenge an issued
patent on limited grounds, including failure to satisfy the novelty or
nonobviousness requirements, which must be argued only on the
basis of prior patents or printed publications.71 Similar to PGR, IPR
challenges are available to anyone with a couple of exceptions. IPR
is not available to the patent owner, nor is it available to those who
have previously sought to invalidate a claim of the at-issue patent
through a civil action.72 Like PGR, the petitioner must also reveal
the real party in interest. Although narrower in scope, IPRs have
quickly proved popular in terms of number of requests.73 IPRs have
also been the focus of much writing.74
69
USPTO Fee Schedule, U.S. PATENT AND TRADEMARK OFFICE,
https://www.uspto.gov/learning-and-resources/fees-and-payment/uspto-feeschedule (last visited Feb. 21, 2018) [https://perma.cc/FAA8-NDT6]. These fees
were increased on January 16, 2018; Nathanael Luman & Kerry S. Taylor, USPTO
to Increase IPR Fees by 33% and PGR Fees by 27% in 2018, KNOBBE MARTENS (Nov. 15,
2017), https://www.knobbe.com/news/2017/11/uspto-increase-ipr-fees-33-andpgr-fees-27-2018 [https://perma.cc/FRM9-28AR].
70 USPTO Fee Schedule, supra note 69. This number does not include any
litigation fees, merely the filing fee.
71 See 35 U.S.C § 311(b) (2012).
72 See id. at § 311(a), 315(a).
73
See Brian Love & Shawn Ambwani, Inter Partes Review: An Early Look at the
Numbers, 81 U. CHI. L. REV. DIALOGUE 93, 93 (2014) (explaining that by late 2014,
almost two thousand requests for IPR were filed since the new procedure launched
in 2011).
74 See, e.g., Scott A. McKeown, PTAB Institution Rate Dips Into 60% Range,
PATENTS POST-GRANT (July 22, 2014), http://www.patentspostgrant.com/ptabinstitution-rate-dips-into-60-range [https://perma.cc/2WXR-XJU8] (discussing
the PTAB institution rates of IPR from February 2013 to July 2014); Michelle
Carniaux & Michael E. Sander, Instituted Patent Claims Survive in About One Third of
All
IPR
Trials,
INTER
PARTES
REV.
BLOG
(Aug.
13,
2014),
http://interpartesreviewblog.com/instituted-patent-claims-survive-one-third-iprtrials/ [https://perma.cc/72DV-E9SC] (calculating that the PTAB had issued 91
Final Written decisions in IPR proceedings as of a little more than a year after the
first was issued); Neal Solomon, The Problem of Inter-Partes Review (IPR),
IPWATCHDOG (Aug. 8, 2017), http://www.ipwatchdog.com/2017/08/08/
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Even newer than the U.S. post-grant proceedings, the Japan
Patent Office (JPO) reintroduced its post-grant proceedings in 2015
after terminating the proceedings in 2003.75 This post-grant system
is, at its core, the same as the opposition system that was terminated
at the end of 2003.76
Like in the European Union and the United States, anyone is
permitted to utilize the Japanese opposition. The Japanese
opposition has the same option offered by the European opposition:
the real party in interest may remain anonymous during the
opposition proceeding. 77 This is simply done by naming a shell
entity instead.78 Yet unlike the European opposition, an opposition
may only be filed with the JPO against an issued patent within the
first six months, not nine months. 79 Moreover, also unlike the
European opposition, the Japanese opposition has many grounds
available to argue, including subject matter eligibility, novelty,
enablement, and inventive step (the equivalent of non-obviousness
in the United States).80 Again, with the priority date changed, often
by one entire year, the patent’s subject matter, novelty, and
nonobviousness are affected.
The filing fees are extremely low for filing a Japanese opposition,
requiring an initial filing fee of about the equivalent of $150 U.S.,
with an additional $22 U.S. for each challenged claim.81 Although
foreign parties will likely need to incur translation fees, the Japanese
opposition system is based only on documental evidence.82 There
problem-inter-partes-review-ipr/id=86287/
[https://perma.cc/Z75K-STCK]
(explaining some criticisms of IPR); Saurabh Vishnubhakat, Arti K. Rai, & Jay P.
Kesan, Strategic Decision Making in Dual PTAB and District Court Proceedings, 31
BERKELEY TECH. L.J. 45, 45 (2016) (analyzing the IPR process in relation to Article III
patent litigation and the administrative state).
75
Miyako Saito & Manabu Hirata, Review of Current Status of Post-Grant
Opposition System in Comparison with Invalidation Trial System, SEIWA PAT. & L. (Apr.
29, 2016), http://www.seiwapat.jp/en/IP/pdf/en00027_PatentOpposition_vs._
InvalidationTrial.pdf [https://perma.cc/E23S-YXZH].
76
PATENT OFFICE LITIGATION, supra note 55, at § 23:16.
77 PATENT OFFICE LITIGATION, supra note 55, at § 23:16.
78 PATENT OFFICE LITIGATION, supra note 55, at § 23:16.
79 PATENT OFFICE LITIGATION, supra note 55, at § 23:16.
80 PATENT OFFICE LITIGATION, supra note 55, at § 23:16.
81
Schedule of Fees, JAPAN PAT. OFF., https://www.jpo.go.jp/tetuzuki_e/
ryoukin_e/ryokine.htm [https://perma.cc/4X7H-G8ZM] (last visited Feb. 7, 2019).
See also Overview of New Post-Grant Opposition System in Japan, SEIWA PAT. & L.,
http://www.seiwapat.jp/en/IP/20150407.html [https://perma.cc/J7ZR-LKV2]
(last visited Feb. 7, 2019).
82 PATENT OFFICE LITIGATION, supra note 55, at § 23:24.
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are no oral proceedings. This helps to keep costs manageable,
especially in regard to the parallel option of invalidation
proceedings.83
Notably, neither the European nor Japanese post-grant
opposition systems have estoppel statutes.84 The lack of an estoppel
statute stands in stark contrast to the post-grant system in the United
States, creating two non-U.S. locations to, as patent practitioners
have noted, “test competitor patent validity.”85
In the United States, there are multiple estoppel statutes, with
the following statute pertaining to the inter partes review:
[t]he petitioner in an inter partes review of a claim in a
patent . . . that results in a final written decision . . . may not
request or maintain a proceeding before the Office with
respect to that claim on any ground that the petitioner raised
or reasonably could have raised during that inter partes
review.86
This means that in the United States, there is one opportunity to
make arguments regarding a particular patent’s claims. If a
particular argument loses, or for strategic reasons a particular
argument is not made, there is no second opportunity to try again.
The petitioner is estopped from making the argument, although
determining what the petitioner “raised or reasonably could have
raised” is not without its own interpretation troubles.87
However, in Europe and Japan, the lack of an estoppel statute
means that if the petitioner loses on one or all of its grounds, it may
See PATENT OFFICE LITIGATION, supra note 55, at § 23:24.
See Karen E. Sandrik, The Post-Grant Life: Coordinating & Strategizing
Challenges of Issued Patents in Multiple Continents, 102 CHI. -KENT J. INTELL. PROP. 449,
455 (discussing the differences in post-grant systems of the United States, Japan,
and the EU, and highlighting the lack of estoppel statutes in Japan and EU postgrant proceedings).
85 Alastair Jones, The Gloves Are Off: Europe is the Location to Test Competitor
Patent Validity, BARKER BRETTELL (Jan. 4, 2018) https://www.barkerbrettell.co.uk/
the-gloves-are-off-europe-is-the-location-to-test-competitor-patent-validity/
[https://perma.cc/56FK-RZ5D] (last visited Feb. 12, 2019). See also International
Post Grant Practice: Strategic Considerations Before the USPTO, EPO and CNIPA,
INTELL. PROP. OWNERS ASS’N, https://www.ipo.org/index.php/ip-chat-channel/
ip-chat-channel-post-grant-proceedings/ [https://perma.cc/RD9D-UDAY] (last
visited Feb. 12, 2019) (explaining “some have noted that in Europe and China,
opposition can be used with little risk as a testing group for the presentation of
arguments that could be used in litigation”).
86
35 U.S.C. § 315(e)(1) (2012).
87 See Sandrik, The Post-Grant Life, supra note 84, at 454-55.
83
84
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repeat the same validity challenges in future proceedings. 88 This
makes opposition systems with no estoppel doctrine quite attractive
as a testing ground for presentation of arguments. With the
combination of no estoppel statute, lower filing fee, ability to stay
anonymous, and proceeding forward with well-known and tried
system, there are relatively little downstream costs for parties to
challenge their competitors’ patents.
In this way, Europe has been the testing ground for challenging
patents for some time now, as well as a patent holder’s willingness
to litigate on multiple fronts to retain key features of the patent, such
as breadth of claims and priority date. The number of Japanese
oppositions has been consistent for a few years, yet, for the reasons
stated above, the post-grant proceedings present a strategic
opportunity that companies will likely take advantage of as part of
a global patent protection and enforcement policy.
Following Japan’s example, Korea reintroduced its post-grant
system in 2017, titling its new process “Request for Patent
Cancellation.” 89 Korea had previously terminated its post-grant
opposition system in 2007. 90 In its earlier version, the post-grant
process was only three months from the publication date of the
patent, yet, with the new system, it is six months (like Japan’s patent
opposition). 91 Similarly, anyone may file a request to cancel a
patent, with grounds specifically including novelty, inventiveness,
and priority.92 Although the fees are incredibly low, like in Japan—
just the equivalent of $10 U.S. per challenged patent—transactional
fees (and local counsel) will quickly increase the total price.
Finally, Korea does have an estoppel statute for all trial
decisions, including a trial for cancellation, that prevents litigants
from re-litigating a patent if an undesirable outcome occurs.93 In this
See Sandrik, The Post-Grant Life, supra note 84, at 455.
PATENT OFFICE LITIGATION, supra note 55, at § 23:46. On the KIPO’s website,
the translation actually comes out to “Application for Revoking Patent.” Patent
Act,
Article
132-2
(Application
for
Revoking
Patent)
(2016),
https://elaw.klri.re.kr/kor_service/lawView.do?hseq=42779&lang=ENG
[https://perma.cc/FFD2-FL7K].
90 PATENT OFFICE LITIGATION, supra note 55, at § 23:46
91 PATENT OFFICE LITIGATION, supra note 55, at § 23:46
92 PATENT OFFICE LITIGATION, supra note 55, at § 23:46 (showing that the priority
challenge is technically listed under the “first-to-file rule” and the “expanded firstto-file rule”).
93 See PATENT OFFICE LITIGATION, supra note 55, at § 23:62 (advising litigants of
the broad estoppel created by an invalidation trial decision and for litigants to
88
89
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way, Korean patent law resembles U.S. patent law more than
Japanese patent law.
Currently, there is no post-grant system available in China. 94
Instead, a petition to invalidate a patent goes through a litigationbased system any time after the patent is granted. This system is
open to anyone wishing to challenge a post-grant patent. 95 The
official fee required to file a request for invalidation is around $475
U.S.96
Part 2, focused on U.S. law, and the next two parts, focusing on
European and East Asian law, will explore particular laws regarding
inventorship, ownership, and patent assignments. There are several
complicating factors here when looking at different laws. One such
complicating factor is the distinction between a common law
country and a civil law country. The United States is a common law
country, with case law providing much guidance even when there
is a statute. Germany is a civil law country, with regulatory law and
statutory law playing a much bigger role. Handling issues of
ownership and assignment through case law versus statute notably
affects the struggle each independent country faces. For the United
States, it is how particular patent assignment law interprets
particular words used in an effective, present assignment versus an
ineffective assignment. In other countries, including Germany, the
Netherlands, and Japan, statutes provide much more guidance. This
creates more certainty but limits flexibility, which constrains parties
and can lead to unnecessary inefficiencies.
2.

EMPLOYEE INVENTIONS & PATENT ASSIGNMENTS IN THE UNITED
STATES

The general rule in U.S. patent law is that the individual inventor
owns what she creates.97 Following this general rule, U.S. patent law
historically required that patent applications be filed in the name of
the individual inventor. Simply, “[a]n Application for patent shall
“coordinate arguments and positions when there are invalidity proceedings in the
other countries that involve the same family of patents”).
94
PATENT OFFICE LITIGATION, supra note 55, at § 23:71.
95 PATENT OFFICE LITIGATION, supra note 55, at § 23:72.
96 PATENT OFFICE LITIGATION, supra note 55, at § 23:72.
97 See Board of Trs. of Leland Stanford Junior Univ. v. Roche Molecular Sys.,
Inc., 563 U.S. 776, 785 (2011) (“Our precedents confirm the general rule that rights
in an invention belong to the inventor.”).
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be made, or authorized to be made, by the inventor . . . “98 The Patent
Act explained that the applicant is the inventor: “The applicant shall
make oath that he believes himself to be the original and first
inventor of the process, machine, manufacture, or composition of
matter, or improvement thereof, for which he solicits a patent . . . .”99
Prior to the AIA, U.S. patent law had just a handful of exceptions
to the general rule that the applicant is the same as the inventor.
These exceptions included the death of the inventor, as well as if the
inventor—obligated to assign her invention to another—either
refused to participate in the filing of a patent application or could
not be found or reached after “diligent effort.”100 In those instances,
another party was permitted to file on behalf of the inventor, but not
without a showing of an assignment, or an agreement to assign in
writing, or that the filing without such a written record is
nevertheless justified and necessary. 101 In the latter instance, the
person making the filing would also need to show a proprietary
interest in the patent application, such as that she formally
employed the inventor. In this way, U.S. patent law has long
required that the inventor be named in the application, even in the
extraordinary circumstance that the inventor was not the actual
applicant.102
This pre-AIA practice of having the inventor, rather than the
company, designated as the “Applicant” on patent applications is
different when compared to other countries. For example, the
Federal Circuit Court of Appeals, the exclusive court of patent
appeals in the United States, has explained that in “many foreign
countries, unlike in the United States, the actual applicant for a

98
35 U.S.C. § 111 (2002) (pre-Leahy-Smith America Invents Act) (emphasis
added).
99 35 U.S.C. § 115 (2013) (emphasis added).
100
See 35 U.S.C. § 118 (2002) (pre-Leahy-Smith America Invents Act)
(explaining that if “an inventor refuses to execute an application for patent, or
cannot be found or reached after diligent effort,” then another person may be able
to file a patent application).
101 Id. (stating that the substitute application is limited to “a person to whom
the inventor has assigned or agreed in writing to assign the invention or who
otherwise shows proprietary interest in the matter justifying such action, may make
application for patent on behalf of and as agent for the inventor on proof of the
pertinent facts and a showing that such action is necessary to preserve the rights of
the parties or to prevent irreparable damage”).
102
37 CFR 1.64 (pre-AIA) (explaining that the substitute statement must name
the inventor, even when the inventor is not filing the patent application herself).

https://scholarship.law.upenn.edu/jil/vol41/iss3/4

2020]

Employee Inventions in a Global Market

781

patent can be other than the inventor, e.g., an assignee.”103 Similarly,
the Manual of Patent Examining Procedure (MPEP) warns:
The requirement that the applicant for a patent in an
application filed before September 16, 2012 be the
inventor(s) . . . and that the inventor or each joint inventor be
identified in applications filed on or after September 16,
2012, are characteristics of U.S. patent law not generally
shared by other countries. Consequently, foreign applicants
may misunderstand U.S. law regarding naming of the actual
inventors causing an error in the inventorship of a U.S.
application that may claim priority to a previous foreign
application under 35 U.S.C. 119.104
Because a goal of the AIA was to bring U.S. patent law closer to
the rest of the world, this requirement was changed. For all patents
filed on or after September 16, 2012, the patent applicant no longer
needs to be the same as the inventor. Instead,”[a] person to whom
the inventor has assigned or is under an obligation to assign the
invention may make an application for patent.”105 Accordingly, a
company may now be designated as the applicant, although the
individual persons are still named as the inventors.106 Importantly,
the AIA also included a change in law, that “[t]he original applicant
is presumed to be the owner of an application for an original patent,
and any patent that may issue therefrom in the absence of an
103
Bos. Sci. Scimed, Inc. v. Medtronic Vascular, Inc., 497 F.3d 1293, 1297 (Fed.
Cir. 2007).
104
MPEP, supra note 27 at 2137.01.
105
35 U.S.C. § 118. See also MPEP, supra note 27, at 605 (detailing this change
in law):
Effective September 16, 2012, the Office revised the rules of practice to permit a
person to whom the inventor has assigned or is under an obligation to assign
an invention to file and prosecute an application for patent as the applicant, and
to permit a person who otherwise shows sufficient proprietary interest in the
matter to file and prosecute an application for patent as the applicant on behalf
of the inventor. See MPEP § 605.01 for information regarding the applicant in
applications filed on or after September 16, 2012.
For applications filed before September 16, 2012, a person to whom the inventor
assigned an invention could file and prosecute an application for patent, but
the inventor is considered the applicant.
See MPEP § 605.02 (2015) for information regarding the applicant in applications
filed before September 16, 2012.
106 See, e.g., U.S. Patent No. 10,212, 827 (filed July 21, 2016) (naming Intel
Corporation as the “applicant” and the individual persons, presumably employees
of Intel, as the “inventors”).
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assignment.”107 Although the new statute regarding this change in
practice does not state that the assignment must be in writing, it does
retain that requirement elsewhere in the Patent Act.108
U.S. patent law is clear that patent assignments must be in
writing, but there is no statutory guidance on the language or
contents of the assignment. This means that employee inventors,
and their respective assignments of any patentable inventions to
their employers, are handled completely by common law.
For example, in terms of assigning the specific priority right of a
patent, U.S. patent law does not require that an assignment of a
patent include an express statement also assigning the right of
priority. Simply, in U.S law, the priority right is regarded as part of
the patent itself. So while the Patent Act does mandate a patent
assignment be in written form, there is no similar mandate
regarding the particular contents of the assignment.109 Also, unlike
other countries, U.S. patent law does not require, nor provide, any
statutory suggestion requiring employers to compensate employees
for their inventions. Any assignment and, or, any form of additional
compensation must be a contractual agreement between the parties.
Before a formal recordation of an assignment from an inventor
to assignee may be filed with the USPTO, it was, and remains after
the AIA, a common practice for employees to enter into contractual
agreements with their employers regarding the transfer of
ownership of any patentable inventions made or conceived during
employment. This occurs after the individual inventor is designated
as the “Applicant” in a patent application.
Because a patent assignment is a contract, the Federal Circuit has
historically applied the contract law of the relevant individual state
when faced with an issue involving a patent assignment. 110 The
Federal Circuit has also previously stated that state courts should
MPEP, supra note 27, at 605.1 (2015).
See 35 U.S.C. § 261 (2012) (“Applications for patent, patents, or any interest
therein, shall be assignable in law by an instrument in writing.”).
109
U.S. patent law does provide advantages to those who record patent
assignments with the USPTO, namely protection against third party buyers or
lenders. See 35 U.S.C. § 261 (2012) (“An interest that constitutes an assignment,
grant or conveyance shall be void as against any subsequent purchaser or
mortgagee for a valuable consideration, without notice, unless it is recorded in the
Patent and Trademark Office within three months from its date or prior to the date
of such subsequent purchase or mortgage.”).
110 See, e.g., Euclid Chem. Co. v. Vector Corrosion Techs., Inc., 561 F.3d 1340,
1343 (Fed. Cir. 2009) (applying Ohio state law after stating that “[c]onstruction of
patent assignment agreements is a matter of state contract law”).
107
108
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determine who owns the patent rights and on what terms. 111
However, the Federal Circuit has, in recent years, also expressed
that U.S. federal law, or more specifically “Federal Circuit law,”
applies to certain instances. 112 The Federal Circuit has explained
that “[a]lthough state law governs the interpretation of contracts
generally . . . , the question of whether a patent assignment clause
creates an automatic assignment or merely an obligation to assign is
intimately bound up with the question of standing in patent cases.
We have accordingly treated it as matter of federal law.”113
U.S. patent law clearly states that “[i]nventions may be assigned
before they are patented.”114 Moreover, U.S. patent law also clearly
states that “[a]n assignment of an expectant interest can be a valid
assignment.”115 However, until the employee does indeed create or
conceive of patentable technology, “the assignee holds at most an
equitable title.”116
Equitable title is distinct from legal title in U.S. patent law. For
example, equitable title is not a sufficient title to bring a suit for
patent infringement; one must have legal title to bring a suit for
patent infringement and seek damages.117 This “expectant interest,”
also known as a future interest, is created when there is an
assignment that is made prior to the actual existence of an
invention.118 It is called an expectant interest because the employee
and the employer are expecting that the employee creates or
111 See, e.g., Jim Arnold Corp. v. Hydrotech Sys., 109 F.3d 1567, 1572 (Fed. Cir.
1997) (“It may seem strange at first blush that the question of whether a patent is
valid and infringed ordinarily is one for federal courts, while the question of who
owns the patent rights and on what terms typically is a question exclusively for
state courts. Yet that has long been the law.”).
112 See Intellectual Ventures I L.L.C v. Erie Indemnity Co., 850 F.3d 1315, 1320,
fn. 1 (Fed. Cir. 2017).
113
DDB Techs., L.L.C. v. MLB Advanced Media, L.P., 517 F.3d 1284, 1290 (Fed.
Cir. 2008) (citations omitted). Despite some inconsistencies in this jurisprudence, it
is now generally understood in the United States that Federal Circuit law governs
the interpretation of the type of patent assignment at issue in the present case. Still,
because of these inconsistencies, district federal courts do sometimes look to state
law for guidance when interpreting patent assignments. See, e.g., Affymetrix, Inc.
v. Illumina, Inc., 446 F. Supp. 2d 292, 296 (D. Del. 2006) (concluding no Federal
Circuit opinion was directly relevant to the language in the at-issue expectant
interest clause and, therefore, it was proper for the court to look to California state
contract law for guidance).
114
Cammeyer v. Newton, 94 U.S. 225, 226 (1876).
115
FilmTec Corp. v. Allied-Signal, Inc., 939 F.2d 1568, 1572 (Fed. Cir. 1991).
116 Id.
117 See Arachnid, Inc. v. Merit Indus., Inc., 939 F.2d 1574, 1579 (Fed. Cir. 1991).
118 See FilmTec Corp. v. Allied-Signal, Inc., 939 F.2d 1568, 1572 (Fed. Cir. 1991).
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conceives a patentable invention at some point in the future during
her employment. Because of this expectation of the creation of
patentable technology, the parties are planning ahead by assigning
the expectant interest in any future inventions by way of a patent
assignment clause. This patent assignment clause is often a part of
a larger employment agreement. Assigning future rights in this way
is permitted under U.S. law.
When an employee assigns an expectant interest to an employer,
one of two situations can occur. The first situation is one in which
the expectant interest clause immediately changes into an
“automatic” or “immediate” assignment; that is, an assignment
transfers legal title to the employer without any further conveyance
or action needed by either party. As soon as the employee creates
an invention, the employer enjoys legal title to that invention. The
second situation is one in which the expectant interest clause does
not immediately transfer legal title once the employee creates an
invention. Instead, the employer, the assignee, remains with just
equitable title. This is often termed an “agreement to assign” or
“obligation to assign.” Thus, the second situation does not result in
the immediate conveyance of equitable-to-legal title, like that which
occurs with an automatic assignment. In this second situation, the
employee has only agreed to assign her invention, meaning the
employer starts with equitable title and ends with equitable title
until some future act of conveyance in writing takes place
transferring legal title to the employer.119
The creation of an assignment that conveys automatic and
immediate ownership compared to a mere obligation to assign
ownership at some future point depends upon the language used by
the parties. 120 Accordingly, the parties distinguish between an
immediate assignment and an obligation to assign a close analysis
of the language. This is important, as this law distinguishes the
United States from much of the world. This unique law, one that
hinges on very particular language, is at issue in seemingly almost
119 Compare FilmTec Corp. v. Allied-Signal, Inc., 939 F.2d 1568, 1573 (Fed. Cir.
1991) (finding expectant interest clause language “agrees to grant and does hereby
grant” creates an automatic assignment), with Arachnid, Inc. v. Merit Indus., Inc.,
939 F.2d 1574, 1580 (Fed. Cir. 1991) (finding expectant interest clause language “all
rights thereto will be assigned” as merely an “agreement to assign, not an
assignment”) (emphasis removed).
120 See DDB Techs., L.L.C. v. MLB Advanced Media, L.P., 517 F.3d 1284, 1290
(Fed. Cir. 2008) (explaining “whether an assignment of patent rights in an . . . is
automatic, requiring no further act on the part of the assignee, or merely a promise
to assign depends on the contractual language”).
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every post-grant European Opposition where the opposition is
challenging the chain of title of the patent that is based on U.S.
priority.
As stated above, an automatic assignment occurs when the
contract expressly grants rights in future inventions. There is no
further act of conveyance needed to effectuate legal title to the
assignee. The Federal Circuit has held that an automatic assignment
was created when the parties stated that the employee “‘agrees to
and does hereby grant and assign’ all rights in future inventions.”121
When using this present conveyance language, the parties seem to
intend no further action is necessary to effectuate the transfer of
legal title from the employee to the employer.122 With the automatic
transfer of the expectant interest, while the individual inventor does
still claim inventorship and most often will designate herself as
“Applicant” pursuant to U.S. law, and had to prior to the AIA, legal
ownership is already with the employer.123
In contrast, when the parties use language that seems to speak
of a future event happening, the Federal Circuit has held that the
parties created only an agreement to assign. For example, an
agreement to assign is conveyed with the following language: “[a]ny
inventions conceived by [Company] or its employees . . . in the
course of the project covered by this agreement, shall by the
property of [Client], and all rights thereto will be assigned by
[Company] to Client.” 124 This “will be assigned” conveyance
language implies that the parties had not intended for the
Id. at 1290.
See also Imatec, Ltd. V. Apple Computer, Inc., 81 F. Supp. 2d 471, 482
(S.D.N.Y. 2001), aff’d 15 F. App/x 887 (Fed. Cir. 2001) (quoting the Invention
agreement which states “I agree to assign, and hereby do assign to [Company] . . .
all my rights to inventions which I have made or conceived . . . .”); SIRF Tech., Inc.
v. Int’l Trade Comm’n, 601 F.3d 1319, 1326 (Fed. Cir. 2010) (“[t]he Employee assigns
all of his or her right, interest, or title in any Invention to the Employer to the extent
allowed by law.”); Preston v. Marathon Oil Co., 684 F. 3d 1276, 1288 (Fed. Cir. 2012)
(“Because the assignment clause in the April Employee Agreement states that the
employee agrees to ‘hereby assign’ all ‘Intellectual Property,’ it is an express
assignment of rights in future inventions that automatically assigned rights to
[Company] without the need for any additional act.”); AgroFresh Inc. v. MirTech,
Inc., 2017 WL 2829627, *13 (D. Del. 2017) (holding that “[Company] hereby assigns
automatically all rights, and all future rights, . . .” is an “assignment [that] is effected
at the moment the” invention is made) (emphasis in original).
123 See Israel Bio-Engineering Project v. Amgen, Inc., 475 F.3d 1256, 1263 (Fed.
Cir. 2007) (explaining “issues of patent ownership are distinct from questions of
inventorship”).
124 Arachnid, Inc. v. Merit Indus., Inc., 939 F.2d 1574, 1576 (Fed. Cir. 1991)
(emphasis added).
121
122

Published by Penn Law: Legal Scholarship Repository,

786

U. Pa. J. Int'l L.

[Vol. 41:3

assignment to occur without some further act of conveyance in the
future. 125 Another example of an expectant interest clause that
merely obligates the employee to convey an assignment of her
creations at a future date reads:
Such Proprietary Developments are the sole property of
[Company], and I agree:
a. to disclose them promptly to [Company];
b. to assign them to [Company]; and
c. to execute all documents and cooperate with HP in all
necessary activities to obtain patent, copyright, mask work,
and/or trade secret property in all countries, [Company] to
pay expenses.126
With this expectant interest clause, the Federal Circuit
determined that the multiple actions contemplated by the parties,
“to disclose,” “to assign,” and “to execute,” demonstrated their
intent for the employee to have obligations to take these actions, not
that legal title would automatically vest in the employer once the
employee conceived of an invention.
The language that expresses the agreement to assign is not
significantly different than that used in an automatic assignment.
Indeed, Justice Breyer has expressed in a U.S. Supreme Court
opinion his concern that “[g]iven what seem only slight linguistic
differences in the contractual language, this reasoning seems to
make too much of too little.”127 At this moment, the Supreme Court
has not taken the opportunity to reconsider this doctrine and
potentially overrule or alter it. Because of the small variance in the
language, federal courts are often faced with very difficult
interpretations of expectant interest clauses. This is especially true
because the very nature of this type of patent assignment seems to
necessarily invoke the use of words like “shall” and “will” when
talking about something that is in the future.
Moreover, parties often combine present language with that of
future conveyance language, as there are several stages of the
patenting process that may require that the employee take further
125
126

2007).

Id. (emphasis added).
IP Venture, Inc. v. Prostar Computer, Inc., 503 F.3d 1324, 1326 (Fed. Cir.

127
See Board of Trs. of Leland Stanford Junior Univ., supra note 97, at 2202-03
(Breyer, J., dissenting).
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actions. When this occurs, it makes the interpretation of the patent
assignment more difficult, thereby opening the door for the court to
decide the outcome (as opposed to the parties in the first instance).
For example, take the following language: “‘Bios hereby conveys,
assigns, transfers and delivers to [Agribiotics, Inc.] all of its right, title,
estate and interest to all its property, assets, business and
undertaking, both real and personal, movable and immovable,
wherever situate [sic] . . . .’” 128 This italicized language seems
similar to the automatic assignment language seen in other opinions
such as FilmTec Corp. or DDB Techs, Inc., yet the dissolution
agreement between the parties also called for Bios to provide any
necessary documentation “for more effectively and completely vesting
the property and assets conveyed . . . or for the purpose of
registration or otherwise.”129
In interpreting these two clauses together, the court determined
that the language in the dissolution agreement was “suggest[ing]
only that Bios will perform any ministerial tasks necessary to
effectuate the transfer of its assets.” 130 Finding the parties had
created an automatic assignment, the court then explained that the
language obligating the assignee to take further steps “does not
undermine the conclusion that the dissolution was a present
assignment of assets to Agribiotics Inc.”131 So despite the language
of “effectively and completely vesting,” no further action was
necessary to create a legally cognizable interest when the invention
was created. There was only the recognition by the parties that more
paperwork in the future would likely be necessary. And while not
citing directly to the applicable state law, for both parties had agreed
federal law controlled this issue, the state law did favor the
approach taken here to carefully ascertain the intent of the parties.132
128 EMD Crop Bioscience Inc. v. Becker Underwood, 750 F. Supp. 2d 1013
(W.D. Wis. 2010) (emphasis added).
129 Id. at 1014 (emphasis added).
130 Id.
131 Id.
132
See Tufail v. Midwest Hosp., LLC, 833 N.W.2d 586, 592 (Wis. 2013)
(“Contract interpretation generally seeks to give effect to the parties’ intentions.”).
When parties cite to state law, or when the federal court feels like it needs further
guidance given the ambiguity of the agreement, employing state contract law or
general principles of contract law may be appropriate. See St. Clair Intellectual
Property Consultants, Inc. v. Palm, Inc. 2009 WL 1220546 (D. Del. May 4, 2009)
(using both present conveyance language and agreement to assign conveyance
language, and where the court used general principles of contract law and Federal
Circuit law to interpret such language).

Published by Penn Law: Legal Scholarship Repository,

788

U. Pa. J. Int'l L.

[Vol. 41:3

In summary, while the individual state law usually governs the
interpretation of contracts, whether the assignment of patent rights
under an expectant interest clause is an automatic assignment or
merely an agreement to assign is a matter of Federal Circuit law.
Federal courts applying Federal Circuit law look closely at the
contractual language used by the parties. And if the at-issue
language seems to expressly convey present rights in future
inventions, no further act of conveyance is required once an
invention is created. The transfer of legal title occurs immediately
by the operation of law. In contrast, if the language in the expectant
interest clause explains that the parties intend for the inventor to
take further steps to convey legal ownership, such as agreeing to
cooperate and execute paperwork to establish ownership, this is
merely an agreement to assign. There is no transfer of legal title;
some other act of conveyance is necessary before legal title is
transferred from employee to employer.
3.

EMPLOYEE INVENTIONS & PATENT ASSIGNMENTS IN EUROPE

When comparing U.S. patent assignment law, most notably in
the employer-employee context, to corresponding law around the
world, there are a couple questions to ask in every instance. First,
does the respective country require, like the United States does, that
the inventor be identified in the patent application? This may occur
by the inventor being the same as the applicant, as is often the case
in the United States, or as the inventor but not the applicant and, or,
owner of the patent. This latter situation is now permitted in the
United States. Second, what is the general rule regarding whether
an employer or the employee owns the invention? In the United
States, the employee generally owns the invention, yet employees
and employers often enter into patent assignment agreements prior
to the creation of any patentable inventions. This causes the
employee’s ownership interests to either automatically vest in the
employer upon creation of the invention, or with some further act of
conveyance. These next two subparts will explore the answers to
these two questions in two different countries: Germany and The
Netherlands.
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3.1. The German Approach
In Germany, as well as under the European Patent Act, the
general rule of patent entitlement is that it shall belong to the
inventor.133 Moreover, only an individual, a natural person, is able
to make the creative contribution necessary to entitle one to a
patent. 134 In this way, a legal entity, a company, cannot be an
inventor under German law.135
That said, it is estimated that between eighty to ninety percent
of all patented inventions in Germany are created by employees.136
Intending to provide rules for balancing the interests under patent
law and labor and employment law for employees-inventors and
employers, Germany has enacted the Employees’ Inventions Act
(ArbEG).137 Most notably, the ArbEG provides employers the ability
to secure ownership of inventions made by their employees, while
also balancing the employees’ interest to reasonable
compensation.138
Under the ArbEG, the general rule holds true: the initial inventor
is the owner.139 Instead of using patent assignment law, through the
form of contract, like the United States does, to change this
ownership, the ArbEG contains a provision providing employers
the right to claim either the transfer of ownership or an exclusive
license to use the invention.140 Not only is there no need to contract
133
See Patentgeseta [PatG] [Patent Act], Dec. 16, 1980, Bundesgesetzblatt
[BHBI] at 501, §6 (Ger.) [hereinafter German Patent Act]. See also European Patent
Convention (EPC), Article 60(1): “The right to a . . . patent shall belong to the
inventor or his successor in title.”
134
As one author stated: “Because an invention comes from a human being,
an inventor cannot be a legal entity.” Alexander Harguth, Patent Ownership in
Germany: Employers v. Employees, MCDERMOTT WILL & EMERY (July 2013),
https://www.jdsupra.com/legalnews/patent-ownership-in-germany-employersv-83560/ [https://perma.cc/43RN-33SZ].
135 Id.
136
Sebastian Wündisch, Employee-Inventors Compensation in Germany—Burden
or Incentive?, 52 LES NOUVELLES - J. LICENSING EXECUTIVES SOC’Y 105 (2017).
137
See Arbeitnehmererfindungesetz, [ArbEG] [Employees’ Inventions Act]
(July 31, 2009) (English translation available at http://www.wipo.int/wipolex/
en/text.jsp?file_id=229680#LinkTarget_642 [https://perma.cc/P8VP-2W3B]). See
also Toshiko Takenaka, Serious Flaw of Employee Invention Ownership Under the BayhDole Act in Stanford v. Roche: Finding the Missing Piece of the Puzzle in the German
Employee Invention Act, 20 TEX. INTELL. PROP. L.J. 281, 284 (2012).
138 See ArbEG, supra note 137, at §§ 6, 9.
139
Takenaka, supra note 137, at 314.
140 See ArbEG, supra note 137, at 19, § 6.
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in the way that employers do in the United States, but any contract
that conflicts with the ArbEG is simply void.141
The ArbEG also clearly defines the scope of this statute and the
inventions that fall under it. There are two types of inventions:
service inventions and free inventions.142 A service invention is one
made or conceived from the employee’s tasks within the scope of
the employer’s business, or, more generally, public
administration.143 A free invention is defined as anything other than
a service invention.144
In practice, for all service inventions, the statute works to create
an obligation on the employee to immediately report any and all
inventions to her employer, or at least “without undue delay.” 145
This reporting requires a detailed description of the invention that
is sufficient for one to understand how and why the invention was
made.146 Upon this reporting, a four-month period is triggered.147
The employer then has four months to decide whether to claim the
invention or not.148 This is an “opt out” period of sorts. In short, if
the employer misses this deadline, the invention is nevertheless
deemed claimed by the employer. Thus, the employer has to
actively opt out of claiming any patentable invention by its
employees. This is a rather recent shift in the statute, with pre-2009
law requiring the employer to actively claim the employee’s
invention. 149 In this way, the former approach was an “opt-in”
approach.150
For free inventions, which should likewise be disclosed like
service inventions upon conception, the employee does not have the
same burden of a detailed report. That said, the employee does need

ArbEG, supra note 137, at § 22.
ArbEG, supra note 137, at § 4(1).
143 ArbEG, supra note 137, at § 4(2). More technically, “[a]n invention made
during a term of employment is a service invention if (1) it resulted from the
employee’s tasks in the employer’s business or public administration, or (2) it is
essentially based upon the experience or activities of the employer’s business or
public administration.” Takenaka, supra note 137, at 315.
144
ArbEG, supra note 137, at § 4(3).
145 ArbEG, supra note 137, at § 5.
146 ArbEG, supra note 137, at § 4(2).
147 ArbEG, supra note 137, at § 5.
148 ArbEG, supra note 137, at § 5.
149 See Wündisch supra note 136, at 105 (explaining this “opt-in” approach was
riddled with errors in practice and prompted the recent change).
150 See Wündisch supra note 136, at 105.
141
142
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to, in essence, adequately explain why the invention falls outside the
scope of her employment.151
Similar to other countries’ patent law, like other countries within
the European Union, 152 as well as Argentina, Hong Kong, and
Korea,153 the ArbEG provides that an employee inventor is entitled
to reasonable compensation, additional to her normal salary, when
her employer claims her invention and uses it. 154 Note, that this
right of additional compensation only arises upon the employer’s
use of the patented technology. 155 The claim for payment occurs
three months after this first use, and continues for the life of the
patent.156 If the patent is invalidated at some point, payments made
to the employee may not be reclaimed by the employer.157
The valuation of this compensation is on a case-by-case basis,
with factors such as the commercial application of the invention,
level of employee contribution and position within the company,
playing a role in determining the reasonable compensation. 158
Moreover, the Guidelines on the Compensation of Employee
Inventions offers a complex formula that takes into account different
fields, from electrical to chemicals and pharmaceuticals. 159 And,
finally, for some industries, such as academia, there is a flat rate,
which is taken from the licensing or other income of the patentable
invention, used to simplify and streamline the remuneration
process. 160 Overall, while there is debate regarding whether
Germany’s regulatory approach to compensation of patentable
See ArbEG, supra note 137, at § 18(1).
Other countries in the European Union similarly have remuneration
statutes, including the Netherlands, Finland, Italy, and Spain. See Scott Foley et al.,
Thinking Globally: Inventor Remuneration Rights, LANDO & ANASTASI (Dec. 8, 2017),
http://www.lalaw.com/news_resources/thinking-globally-inventorremuneration-rights/ [https://perma.cc/NC9K-6QZ9].
153 See id. See also Orly Lobel, The New Cognitive Property: Human Capital Law
and the Reach of Intellectual Property, 93 TEX. L. REV. 789, fn. 148 (2015) (“Germany,
the United Kingdom, France, and Finland all require fair compensation to the
employee for any assigned invention” and “China and Japan similarly guarantee
employee-inventions a reward for assigned work.”).
154 See ArbEG, supra note 137, at § 9(1).
155 See ArbEG, supra note 137, at § 9(1).
156 See Wündisch supra note 136, at 106.
157 See Wündisch supra note 136, at 106.
158 See Wündisch supra note 136, at 106.
159 See ArbEG, supra note 137, at § 9(1).
160 See Wündisch, supra note 136, at 109 (explaining “German law has a special
provision granting the university inventor a flat rate of 30 percent of the income
from the utilization proceeds of the university”).
151
152
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inventions in the employment context provides desirable incentives
that lead to maximum creativity and ingenuity, empirical research
has confirmed “that the law creates substantial monetary rewards
for productive inventors.”161
3.2. The Dutch Approach
The Dutch Patent Act of 1995 governs patent assignments,
including those assigned in the employer-employee relationship, via
statute.162 The language of Article 12.1 states the general rule: the
employee-inventor is the entitlement owner.163 The exception to this
general rule is when the nature of the employee’s job is to make
inventions of the type at issue. Let’s call this the “employee
exception.” In full:
If the invention for which a patent application has been filed
has been made by a person employed in the service of
another party, the employee shall be entitled to the patent
unless the nature of the service entails the use of the
employee’s special knowledge for the purposes of making
inventions of the same kind as that to which the patent
application relates, in which case the employer shall be
entitled to the patent.164
There are some patent commentators that feel the opposite is
true: that actually the general rule is that the employer is the owner
of the patent, with the exception that the employee might own the

161
Dietmar Harhoff & Karin Hoisl, Institutionalized Incentives for Ingenuity—
Patent Value and the German Employees’ Inventions Act, 36 RES. POL’Y 1143 (2007),
https://www.sciencedirect.com/science/article/pii/S0048733307001497
[https://perma.cc/2GAL-ZMLM].
162
Patent Act 1995 (Rijksoctrooiwet 1995) [hereinafter Patent Act 1995], the
unofficial translation is available at https://www.ivir.nl/syscontent/pdfs/163.pdf
[https://perma.cc/R3SB-4KZY].
163 Id. at Article 12.1. This entitlement is for both the patent application and
resulting patent. See also The International Association for the Protection of
Intellectual Property, Netherlands Report Q183, at 6 [hereinafter AIPPI],
[https://perma.cc/8X5M-CSHN] (explaining the courts’ application of Article
78.1 of the Patent Act, which states that ownership of the patent can be claimed by
the person who is entitled to the patent based on Article 12 of the Patent Act).
164 See Patent Act 1995, supra note 162, at Article 12.1.
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invention.165 Presumably, this opinion comes from the observance
that in many instances, the employee at question will be hired
specifically to create or be a part of a team that creates innovation.
Moreover, practitioners do not want the employer to need to get a
separate agreement from the employee, which “may lead to
difficulties, e.g., when the employee cannot be traced or refuses to
co-operate with such a transfer.”166
Two examples of this occurred, at least in part, due to the preAIA U.S. law requiring that employees/inventors serve as the
applicants of U.S. patent applications. In these two examples, an
employee refusing to execute documents needed to assign U.S.
patent applications to the employer.167 This serves as another reason
that international harmonization is so important. It is hard to trace
the chain of title when there are different requirements on which
party must serve as the applicant, which may or may not be the same
as the owner from one country to another.
Beyond the traditional employer/employee context, the Dutch
Patent Act contains a similar provision for patents created “in the
context of training course,”—the trainee exception, and for patents
in the field of research or service at a university, college or research
institution—the researcher exception. In the training exception, “the
party for whom the services are performed shall be entitled to the
patent[,] unless the invention has no connection with the subject of
the services.”168 In the researcher exception, the statute, in essence,
assumes that the invention was made pursuant to one carrying out
“research in the service of a university, college or research
establishment, [then] the university, college or research
establishment shall be entitled to the patent.”169
165 See AIPPI, supra note 163, at 15 (explaining “the group is of the opinion
that if the requirements for entitlement of the employer to the in-tellectual
property rights in the employee’s creation have been fulfilled (e.g. the
requirement that making creations like the creation in question must have been
part of the employee’s employment), the employer should be the owner of the
intellectual property rights from the outset.”).
166 AIPPI, supra note 163, at 15.
167 See AIPPI, supra note 163, at 15.
168 See Patent Act 1995, supra note 162, at Article 12.2.
169 See Patent Act 1995, supra note 162, at Article 12.3. Note here that “Article
12 makes a distinction between employees in the private sector (article 12.1: entitled
to their inventions unless the making of such inventions was part of the
employment) and researchers at a university or research institute (article 12.3:
inventions made by these researchers always belong to the university or research
institute)”. AIPPI, supra note 163, at 10.
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Finally, the Dutch Patent Act also permits parties to change,
pursuant to a written agreement, the general rule of Article 12.1, as
well as its exceptions and the provisions regarding inventions made
connected to training courses and research.170 These rules all govern
what we would term “employees” in the United States, that is, not
independent contractors. 171 These provisions specifically cover
employees who have an employment contracts, as meant in the
Dutch Civil Code, and to civil servants employed by the government
or other public institutions, such as a public university or research
institution. 172 If an employee does not have a contract, then the
default rule applies: the employee enjoys the rights to her
inventions. 173 Accordingly, parties and courts must look to the
agreement to determine the scope of one’s employment and
expectation regarding future inventions. If parties simply use
language that invokes the Dutch Patent Act, there will not be the
parsing of language like there is in the United States. Indeed, there
are “few disputes . . . brought before the court” regarding patent
ownership and use of rights over inventions made or conceived in
the workplace.174
Two rules that parties are not permitted to opt out of or change
via contract, are the right as an inventor to be identified as such in
the patent application and the remuneration statute. Like in the
United States and elsewhere, the inventor has a right to be identified
as the inventor. 175 While in the United States, this right is not

170 See Patent Act 1995, supra note 162, at Article 12.5 (“The provisions of
paragraphs (1), (2) and (3) may be departed from by written agreement.”).
171 See Wouter Pors, Employee Inventions in The Netherlands, Y.B. LES
NOUVELLES 117, 118 (June 2017), http://birdbuzz.nl/wpcontent/uploads/2017/07/2017-07-Pors-Employee-Inventions-In-TheNetherlands.pdf [https://perma.cc/D9VD-AFMT] (stating that the employee
exception “doesn’t cover free lancers, self-employed workers or managers who
don’t have an employment contract (but for instance a management contract
between their personal legal entity and the company)”.
172 Id.
173 Id.
174
AIPPI, supra note 163, at 13.
175 See Patent Act 1995, supra note 162, at Article 14 (“Any person who has
made an invention for which a patent application has been filed, but who cannot
claim any title to a patent on the ground of Article 12(1), (2) or (3) or under an
agreement concluded with the applicant or his predecessors in title, shall have a
right to be named as the inventor in the patent.”).
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attributed as a “moral” right, it is commonly so throughout
Europe.176
Also, somewhat common in Europe is the remuneration statute
in the Dutch Patent Act regarding employee compensation for
patents. This remuneration statute covers the employee, trainee,
and research exceptions: where the “employer” is entitled to the
patent, not the inventor. Article 12.6 states that
In the event that the inventor cannot be deemed to have been
compensated in the salary he earns or the pecuniary
allowance he receives or in any extra remuneration he
receives for not having been granted a patent, the party who
is entitled to the patent on the basis of paragraphs (1), (2) or
(3) will be obliged to grant him equitable remuneration
related to the pecuniary importance of the invention and the
circumstances under which it was made. Any right of the
action on the part of the inventor in accordance with this
paragraph shall lapse after the expiry of three years from the
date of the grant of the patent.177
As to the determination of whether an employee/inventor
should receive extra compensation, that beyond the employee’s
normal wages, is one that seems troubling on the surface, but is not
as much in practice. The Supreme Court has, on at least two
occasions, stepped in to clarify and provide guidance to Article
12.6.178 In both opinions, the Supreme Court held that the invention
created was within the scope of the employee’s employment,
thereby supporting the conclusion that the employee’s normal
wages cover the possibility of a patentable invention. It is only in
the “exceptional circumstances [that] [] the employee [will] be
entitled to additional compensation.”179

176 See AIPPI, supra note 163, at 1-2 (explaining that is a “mandatory” rule and
a “(moral) right of the employee to be mentioned as the inventor in the patent”).
177 See Patent Act 1995, supra note 162, at Article 12.6 translated in Patent Act
1995,
Netherlands
Enterprise
Agency
(Sept.
18,
2009),
https://english.rvo.nl/topics/innovation/patents-other-ip-rights-topic/patentlaw/patent-act-1995 [https://perma.cc/2ZKR-F4VR].
178 AIPPI, supra note 163, at 6 (identifying two cases, including a claim for
compensation of the employee and a decision of a public entity regarding
compensation).
179 AIPPI, supra note 163, at 11.
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EMPLOYEE INVENTIONS & PATENT ASSIGNMENTS IN EAST ASIA

Similar to the two parts above, this part will detail who has the
first right to the patent, the inventor or the company, in Japan,
Korea, and China. In the case that there needs to be a patent
assignment, this part will also describe the patent assignment laws
that are unique to each country.
4.1. The Japanese Approach
Unlike in the United States, where, at least until very recently,
most patent applicants are the inventor, in Japan, most patent
applicants are the assignees, not the inventors.180 Seeking to address
a myriad of shortfalls in its employee invention law under the
Japanese Patent Act,181 amendments were made in 2004 and 2015,
effective on April 1, 2016, to the employee inventions statute. 182
Japanese patent law is more like that of Germany and Netherlands,
than the United States, in that its statutory law seeks to answer many
of the basic questions of inventorship and ownership in the first
instance. 183 It is also like Germany and others in that only an

180
Mary LaFrance, A Comparative Study of United States and Japanese Laws on
Collaborative Inventions, and the Impact of Those Laws on Technology Transfers, 2005
INST. INTELL. PROP. BULL. 86, 91 (2005), http://scholars.law.unlv.edu/cgi/
viewcontent.cgi?article=1435&context=facpub
[https://perma.cc/9ESR-XPF6]
(stating that “patent applicants in Japan are typically not the actual inventors, but
their assignees”).
181 See Tokkyoho Patent Act [hereinafter Tokkyoho Patent Act], Law No. 121
of 1959, Art. 35, translated in Patent Act (Act No. 121 of 1959),
http://www.cas.go.jp/jp/seisaku/hourei/data/PA.pdf
[https://perma.cc/PEU9-S9KC], the unofficial translation is available at
http://www.japaneselawtranslation.go.jp/law/detail/?printID=&ft=1&co=01&x
=32&y=19&ky=%E7%89%B9%E8%A8%B1%E6%B3%95&page=10&id=42&lvm=&
re=02&vm=02 [https://perma.cc/DCF3-39FW]. This foundation remains in
today’s law. For example, Article 35 of the Japanese Patent Act of 1959 stated that
when an employee obtained a patent, an employer enjoyed a non-exclusive
license. Article 35 was amended to, most notably, address the remuneration
portion of the statute. See also Takashi Suzuki, Progress Report: Amendment of
Article 35 (employee invention) of the Japanese Patent Act, JAPAN INTELL. PROP. ASS’N 4
(Apr. 22, 2015), http://www.jipa.or.jp/english/activities/others/pdf/
150422JIPA-AIPLA%20Meeting.pdf [https://perma.cc/A827-RNN6].
182 See generally Tokkyoho Patent Act, supra note 181.
183 See generally Tokkyoho Patent Act, supra note 181.
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individual, a natural person, can be the inventor.184 Accordingly, the
general rule is that patent ownership is first vested with the
individual inventor. The fact that most applicants are not the
inventors demonstrates the high importance of patent assignment,
either via statute or common law, in Japan.
Article 35, the employee inventions statute, has five subsections.
The first subsection is unchanged from the former law. Most simply,
if the employee-inventor receives a patent that is within the scope of
her employer’s business, then the employer has a royalty free, nonexclusive license to the patent. Like Germany and Netherlands, this
law applies to both private and public industries.185
The second subsection then explains that an invention made by
an employee that is not captured within the first subsection because
it is, in essence, outside the scope of the employee’s work, it does not
automatically vest in the employer, nor can it be assigned ex ante to
the employer. In fact, any such “contractual provision . . . providing
in advance that the right to obtain a patent for such an invention
shall belong to the employer . . . shall pass to the employer, etc. or []
shall have a provisional exclusive license or exclusive license on
such an invention shall be null and void.”186 This section is largely
unchanged from the former statute, with simple language added for
clarification. This section makes sense as it carves out inventions
made by employers that are presumably conceived on their own
time and outside the scope of their job. Of course, what does and
does not “correspond to an employee invention” is not necessarily
clear cut. The next section briefly discusses what does “correspond
to an employee invention”, a 2015 amendment.
This third subsection explains that when an invention is made
by an employee that does, in fact, correspond to an employee
invention, it can be assigned to the employee prior to the conception

184 Masayuki Yamanouchi & Makoto Ono, Patents, GETTING THE DEAL
THROUGH (Mar. 2019), https://gettingthedealthrough.com/area/25/
jurisdiction/36/patents-2017-japan/ [https://perma.cc/ZH67-TFZW].
185
See Tokkyoho Patent Act, supra note 181. The first subsection states: “An
employer, a legal entity or a state or local public entity [the “employer”] . . . shall
have a non-exclusive license on the patent right concerned.” See also Naohisa
Akashi & Manabu Hirata, Revisions Made to the Japan Patent Law Relating to
Employee Invention System, SEIWA IP NEWS 6 (May 20, 2016),
http://www.seiwapat.jp/en/IP/pdf/en00029_Employee%27s_Inventions_Refor
m.pdf [https://perma.cc/PWH9-RTB5] (comparing the old and new laws side by
side).
186 See Akashi & Hirata, supra note 185, at 6 (emphasis added).
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of the patent.187 In this way, Japanese patent law is similar to the
U.S. common law equivalent of the automatic assignment of an
expectant interest without requiring a strict parsing of language.
The shall language, which is used in the statute, is not sufficient to
pass legal titles under U.S. law, but it is under Japanese law. In
summary, this third subsection is clear that “[f]or an invention
created by an employee, the right to obtain a patent may be assigned
to an employer or even originally acquired in accordance with rules
established by the employer, and the said employer may file the
patent application as the applicant.”188
The fourth subsection is an employee invention remuneration
statute. It was amended in 2004, and then again in 2015. It explains
that the employee “shall have the right to a reasonable money or
other reasonable economical profits . . . when he has enabled the
right to obtain a patent for an employee invention to belong to the
employer, etc.” 189 The final subsection elaborates on what is
reasonable, by explaining that compensation “shall not be
considered to be unreasonable” where there has been a negotiation
between the parties, the employer and employee, that was carried
out with some of established policy or criteria. This is largely the
same as the former statute, and affirms case law that “emphasizes
the importance of adopting reasonable procedures to determine the
amount of remuneration awarded.”190 With the latest amendment,
and similar to that seen in relation to reasonable compensation
under the German employee inventions statute, ArbEG, there are
guidelines provided to help this determination.191
187 See id. (“In the case of an invention made by an employee, etc., which
corresponds to an employee invention, when there is a contractual provision . . . in
advance that the right to obtain a patent for such an invention shall belong to the
employer, etc., the right to obtain a patent for such an invention shall inherently be
vested in the employer, etc., since the occurrence of the right.”)
188 Tokkyoho Patent Act, supra note 181, Art. 35.
189
Tokkyoho Patent Act, supra note 181, Art. 35. Cf. Steven Cherensky,
Comment, A Penny for Their Thoughts: Employee-Inventors, Preinvention Assignment
Agreements, Property, and Personhood, 81 CALIF. L. REV. 595, 623 (1993) (“It is worth
noting that the American system of uncompensated contractual cognitive
assignment is an exception among highly innovative countries. In the United States,
private employers have no affirmative duty to compensate employees for profits
derived from their inventions.”).
190
LaFrance, supra note 180, at 92.
191
See Hiroshi Morita, The Employee Invention in Japan, EU-JAPAN POLICY
SEMINAR 7 & 12 (Nov. 22, 2016), http://www.eu-jp-tthelpdesk.eu/wp-content/
uploads/2016/11/Hiroshi_Morita-Employee_Invention.pdf
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Due in part to the remuneration statute, and
[b]ecause Japanese patent law does not distinguish
deliberate misrepresentations from inadvertent errors in this
context [joint inventorship, omitting a joint inventor], even
an honest mistake as to inventorship, or as to the validity of
an assignment agreement, could lead to invalidation. This
result seems unjust with respect to the excluded inventors or
assignees who acted without fraudulent intent, since the
invalidation will extinguish their patent rights.192
Errors in the chain of title may also have a significant impact on
the question of reasonable remuneration.193
Finally, in terms of patent assignments, Japanese patent law
requires that all assignments changing the ownership of a patent be
registered in the patent registry of the JPO. The documents
necessary for this change in ownership are the original or certified
copy of the patent assignment itself and a power of attorney.194
4.2. The Korean Approach
The Korean Invention Promotion Act explains that the
ownership of a patent originally vests in the employee-inventor, at
least absent any contractual agreements or any specific employment
regulations.195 The employer is entitled to a non-exclusive license
for the patent right that the employee acquires after completing the
patent process. This is premised on the idea that the employer
should have at least a non-exclusive license due to its contributions
[https://perma.cc/MRZ6-5QYA] (introducing the background of employee
invention law in Japan and recent revisions).
192
LaFrance, supra note 180, at 91.
193 See LaFrance, supra note 180, at 91 (arguing that errors in inventorship have
serious impacts on remuneration under Japan Patent Act Section 35).
194
Arpita Bhattacharyya, Inventor Oath or Declaration and Assignments, Full
Disclosure, IP5 OFFICES (Feb. 2016),
https://www.finnegan.com/files/Upload/Newsletters/Full_Disclosure/2016/F
ebruary/FullDisclosure_Feb16_3.html [https://perma.cc/AU2A-HCWN].
195
Jihyun Kim et al., IP in Business Transactions: South Korea Overview,
PRACTICAL LAW COUNTRY, Q&A 4-501-7300 (Dec. 1, 2018), https://content.next.
westlaw.com/Document/I2ef129481ed511e38578f7ccc38dcbee/View/FullText.ht
ml?contextData=(sc.Default)&transitionType=Default&firstPage=true&bhcp=1
(introducing that the ownership of patent vests in the employees originally under
question No. 22).
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that lead to the patentable invention of the employee-inventor in the
first instance.
Of course, employers do not just want a non-exclusive license,
and the Korean Invention Promotion Act recognizes this by
permitting employers to use the mechanism of a contractual
agreement to alter the original vesting of ownership in the
employee. With an employment agreement, for example, much like
the United States, Korean employers can require their employees to
transfer all rights to future patentable inventions prior to their
creation. 196 If the ownership has already vested in the inventor,
meaning there was no contractual agreement in place, and the
employee decides to assign her inventor to her employer, or, for
example, an independent contractor sells her patent rights to a
company, the patent assignment must then be recorded with the
KIPO. 197 The requirements of registration include: (1) a deed of
assignment that is executed by the assignor, (2) a Notarized
Corporate Nationality Certificate, also executed by the assignor, and
(3) a power of attorney of the assignor and the assignee.198 Unlike in
the United States where a recordation of a patent assignment is not
required for it to be effective, Korean patent law requires the above
three steps before the patent assignment is effective.199
Finally, in the case that the employee must transfer to her
employer the right to acquire, she is entitled to receive fair
compensation.200 Many commentators contend that this right to fair
or justifiable compensation cannot be waived by a contractual
agreement. 201 If the employee feels the compensation is not
reasonable, she can challenge the amount. If a court indeed decides
the “compensation is unreasonable, a court can decide the amount
196
Yoon Suk Shin, Eun-Young Park, & Gon-Uk Huh, Patents, GETTING THE
DEAL THROUGH (Mar. 2019), https://gettingthedealthrough.com/area/25/
jurisdiction/35/patents-korea/ [https://perma.cc/B7ZF-NG9E].
197 See id. (introducing that the patent assignment shall be recorded before
KIPO).
198
Bhattacharyya, supra note 194, at 2.
199 See Bhattacharyya, supra note 194, at 2 (showing the differences in patent
assignment laws in different countries and regions).
200
See Jihyun Kim et al., supra note 195 (explaining that The Invention
Promotion Act provides a right of fair compensation for employees).
201
Mikyung Choe & Yoon Chang Lee, The Challenges of Patent Applications for
International Collaborations, KIM & CHANG 2 (Dec. 15, 2014),
https://www.internationallawoffice.com/OnDemand/IntellectualProperty/The-challenges-of-patent-applications-for-internationalcollaborations/South-Korea/Kim-Chang [https://perma.cc/7WBX-WLZA].
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of the compensation by taking into account the profit earned by the
employer based on the employee’s invention, along with any other
circumstances relating to the [intellectual property rights].”202
4.3. The Chinese Approach
Chinese patent law divides inventions into two categories: nonservice invention-creation and service invention-creation. 203 For
non-service invention-creations, the ownership of the invention
vests in the inventor herself.204 In contrast, for service inventioncreations, what we generally think in the United States as employee
inventions, the ownership of the invention vests directly to the
inventor’s employer.205
Like Germany, Japan, and Korea, Chinese patent law has specific
laws regarding the compensation of employee inventors.
Specifically, Chinese patent law and its Implementation Rule state a
basis for inventor rewards (one-time payments) and remuneration
(royalty payments), yet other authorities in the country have issued
their own regulations.206 These various remuneration statutes are at
conflict with each other, with some practitioners commenting on the
inconsistency.207
In terms of actual recordation, and the recognition of
recordation, of ownership changes, Chinese patent law is somewhat
unique to the other IP5 countries. While patent assignments are
permitted, all assignments to a “foreigner, foreign enterprise, or
other foreign organizations must be approved by the relevant
department under the State Council.”208 Moreover, if the right to
apply for a patent is assigned, as in the case of an employee
Id.
Jeffrey P. Langer, Proposed Changes to China’s Inventor Reward and
Remuneration System, OSHA LIANG (July 25, 2017), https://oshaliang.com/
newsletter/proposed-changes-to-chinas-inventor-reward-and-remunerationsystem [https://perma.cc/YE8W-B9P8].
204 Id. ¶ 2.
205 Id. ¶ 2.
206
Xiunan Jin, Case Study: How to Reward and Remunerate Inventors in China?
IPWATCHDOG (Oct. 13, 2016), http://www.ipwatchdog.com/2016/10/13/rewardremunerate-inventors-in-china/id=73533/ [https://perma.cc/A9N8-S555].
207 See, e.g., id. (stating that inconsistency exists regarding the amount of the
inventor remuneration and industries stakeholders are uncertain how the laws will
be applied and interpreted).
208
Bhattacharyya, supra note 194, at 2.
202
203
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assigning her future rights to apply for a patent, a written
contractual agreement between the parties must be “registered with
the patent administration department under the State Council.”209
5.

MOVING TOWARDS TRANSPARENCY & PREDICTABILITY

As Part 1 identified, proving patent priority is fundamental to
the successful granting, in the first instance, and, the focus of this
Article, the defense of a post-grant patent. As the different
approaches taken in the IP5 countries demonstrate, there are various
ways to structure the initial decision of ownership and identification
of inventor, as well as to transfer or otherwise assign the ownership
of the patent by statutes or individual contractual agreements.
What is clear in all of these approaches is that ex ante
transparency and predictability of patent priority would reduce
transaction and litigation costs. It would reduce transaction costs,
when either practitioners are taking on a new client or assessing an
infringement action (whether as plaintiff or defendant) for a current
client, as the practitioner would be able to quickly assess patent
ownership and the effective global date. In this way, they would not
need to do extensive file searching, retroactive assignments, or go
through patent error correction with their local or foreign patent
office. If they do need to take those measures, it will be out of
certainty of a position, rather than a “just-in-case” position.
Further, more transparency and higher predictability regarding
global priority dates prior to post-grant opposition proceedings or
invalidity litigation would reduce litigation costs, as well as
certainly, as parties would know quickly whether a priority
challenge is likely to win or not in a post-grant challenge. Currently,
due to the disparate patent assignment laws and procedures, there
is unpredictability that favors an expensive litigation strategy. This
litigation strategy involves simply challenging priority to try and
obtain information that may disrupt the effectiveness of the at-issue
patent. Patent holders that are particularly likely to see this sort of
priority challenge are those that have gone through mergers,
acquisitions, or other structural changes, ones that may affect the
ownership of patents. Moving towards better transparency and
predictability of global patent priority is the focus of the two new
proposals.
209

Bhattacharyya, supra note 194, at 2.
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5.1. Utilizing Current Secured Transactions Recordation Systems
In a 2016 study conducted by AIPPI, the International
Association for the Protection of Intellectual Property, groups
representing different countries responded to a questionnaire
regarding whether the group’s current law permitted the possibility
of creating security interests over intellectual property rights.210 Out
of the more than forty countries that responded, just three
responded in the negative. 211 Each group was generous in their
response regarding their respective country’s adoption of a secured
transactions law, often explaining how their respective secured
transaction worked in their country.
This study and its responses evidences a level of comfort in
secured transactions law throughout the world. For all five IP
Offices, the countries in which they are housed responded that they
did indeed permit parties to grant security interests in patents.
Moreover, they responded “yes” to the following question: “Is your
Group’s current law regarding security interests over IPRs sufficient
to provide certainty and predictability to the parties?”212 Moreover,
countries that do not provide “visible records” (searchable
recordation system), like Germany, still feel that parties practicing
within Germany have sufficient predictability and certainty
regarding their secured transactions laws.
For a bit more detail on secured transactions in practice, consider
the United States, for example. In the United States, the drafters of
210 AIPPI, Summary Report—Security Interests Over Intellectual Property (2016),
http://aippi.org/library/summary-report-general2016/
[https://perma.cc/5U9M-2Q3D].
211 Id.
212
Id. at 10. See also AIPPI, Netherlands: Security Interests Over Intellectual
Property (2016), http://aippi.org/library/security-interests-over-intellectualproperty-40/ [https://perma.cc/2GHS-ZKWY]; AIPPI, Germany: Security Interests
Over Intellectual Property (2016), http://aippi.org/library/security-interests-overintellectual-property-24/ [https://perma.cc/7739-N8LZ]; AIPPI, Republic of Korea:
Security Interests Over Intellectual Property (2016), http://aippi.org/
library/security-interests-over-intellectual-property-18/ [https://perma.cc/J59VZZM7]; AIPPI, Japan: Security Interests Over Intellectual Property (2016),
http://aippi.org/library/security-interests-over-intellectual-property-14/
[https://perma.cc/32YZ-JZMG]; AIPPI, China: Security Interests Over Intellectual
Property (2016), http://aippi.org/library/security-interests-over-intellectualproperty-6/ [https://perma.cc/4M8J-7YKV]; AIPPI, United States of America:
Security Interests Over Intellectual Property (2016), http://aippi.org/
library/security-interests-over-intellectual-property-34/ [https://perma.cc/674HWLD3].
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the Uniform Commercial Code (“UCC”) developed Article 9, the
law of secured transactions, from “a motivation to encourage
lending practices.”213 Most basically, the drafters determined that if
the law could help reduce a lender’s risk and cost to lend, and
thereby increase predictability and certainty, then a lender should
be more willing to enter into transactions with debtors. 214
Recognizing the need for a uniform system, one that was not
impacted by individual rules with states, as well as a central place
for parties to gather information about what financial transactions
might affect them, the UCC drafters created a uniform, one-page
UCC financing statement that can be filed online in a matter of
minutes in each state and province, including D.C. for foreign
entities, among others. The UCC recordation system has a pure
notice function: the financing statement is not detailed, but it must
contain accurate information on the debtor’s name, the creditor’s
name, and collateral that is covered.215
While countries surveyed here have aspects that are unique in
their secured transactions law, as financing law is typically tailored
towards the needs and culture of each respective country,216 there is
also a notable commonality. Secured transactions laws must be
predictable, no matter what country they are operating in. Why?
The reason is the same everywhere: third parties rely on this
information when deciding to lend credit to a debtor. Again, third
parties do not need access to much detail of any given transaction,
but they must know who the debtor is, who the creditor is, and what
the general collateral is.
In a similar way, patent law needs a central, online recordation
system for patents. This would not be necessary for patents that are
used as collateral to help secure financing, like what the AIPPI
213
Karen E. Sandrik, Formal but Forgiving: A New Approach to Patent
Assignments, 66 RUTGERS L. REV. 299, 340 (2014).
214 See U.C.C. § 9-101 (1962), official comment (“The aim of this Article is to
provide a simple and unified structure within the immense variety of present-day
secured financing transactions can go forward with less cost and with greater
certainty.”).
215 See id. at 7, § 9-502 (introducing the financing statement formal requisites).
216
See AIPPI, Japan: Security Interests Over Intellectual Property, supra note 212,
at 10 & 14, http://aippi.org/library/security-interests-over-intellectual-property14/ [https://perma.cc/32YZ-JZMG] (The report from Japan demonstrates this
uniqueness most visibly, answering “no” to whether it would be desirable to
harmonize laws governing security interests in IPRs. The reasoning: trying to move
away from unique national law would create instability and unpredictability in the
financial markets in Japan and likely around the world).
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survey was specifically inquiring about, but a central place where
the ownership of patents can be registered for all to see. This is
purely about providing sufficient notice of what the global effective
date is for any patent, as well as the ownership of the patent. This
information should show the chain-of-title, much like what local
county property offices do for real property here in the United
States.
Unfortunately, as the systems are currently set up, again, using
the United States as a specific example, the systems are designed
specifically to gather information regarding a debtor, creditor, and
collateral. The secured transactions systems are not designed to ask
information about a patent applicant or a patent owner, let alone the
effective global date of a patent itself. Certainly, it would not be a
difficult task, at least compared to most law reform, to enable the
online systems to intake this information, but it would mean some
technical overhauling of the online systems and patent laws in each
country.
Yet, even if this does not ever happen, looking to the consistent
and predicable secured transactions laws across the world that
almost all use some sort of quick, online recordation systems, can at
least lead to the adoption of similar one-page per patent filing
systems for tracking the chain-of-title of patent ownership.
5.2. Requiring Ex Ante Disclosures
The above section argued that secured transactions law, with its
notice function of recordation, should provide an example, if not inplace model, for creating more predictability and certainty for
patent priority in a global market. This subpart suggests that either
coordinating with a centralized recordation system, one that would
be online for anyone to search, or building new disclosure
requirements into an already-existing system, would create a
common notice system in regard to the priority date of patents.
A centralized recordation should likely be housed at the World
Intellectual Property Organization (“WIPO”), which is also the place
where PCT applications are filed as a part of fulfilling its mission.
The WIPO is also ideal space, as its mission is to “promote[]
innovation and creativity for the economic, social and cultural
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development of all countries, through a balanced and effective
international intellectual property system.”217
As stated above, the PCT, the Patent Cooperation Treaty,
sometimes also referred to as the “international patent system,”
helps patent applicants seek patent protection in countries outside
of their local country.218 Patent applicants can file an international
patent application, which will then jumpstart a process to selecting
one or more of the 153 PCT Contracting States, from the United Arab
Emirates to Zimbabwe, and many in between.219
When filing the international patent application under the PCT,
the patent applicant has the opportunity to use the priority date of a
national, or local patent. For example, if a patent is first filed in
China, the patent owner then has up to twelve months to file the
patent application, link it, and use the priority date of the Chinese
patent. Accordingly, adding very specific questions that would
auto-fill into a centralized database would be relatively easy.
Simply, where is the country of origin? What is the claimed effective
priority date? Who is the patent owner of the Chinese patent? Who
is the PCT applicant? Ideally, of course, the last two questions will
have the same answer. If the answers are not the same, it will at least
trigger an automatic inquiry by WIPO and the patent applicant
herself. This automatic function would also function to help bring
notice to the potential chain-of-title immediately, as opposed to
having memories and records stale for years before the issue is ever
noticed.
This same type of centralized recordation system, if not housed
by WIPO, could also be a simple add-on to the unitary patent
system. The EPO has stated that the unitary patent system is
scheduled to launch by the end of 2020.220 Given that many of the
priority challenges are occurring in EU oppositions, this simple yet
217 See Homepage, WORLD INTELL. PROP. ORG., https://www.wipo.int/portal/
en/index.html [https://perma.cc/CQQ7-9G7U] (last visited on Mar. 3, 2019).
218
See The PCT now has 153 contracting states, WORLD INTELL. PROP. ORG.,
https://www.wipo.int/pct/en/ [https://perma.cc/JBX2-JXU4] (last visited on
Mar. 3, 2019) (explaining “The Patent Cooperation Treaty (PCT) assists applicants
in seeking patent protection internationally for their inventions . . . By filing one
international patent application under the PCT, applicants can simultaneously seek
protection for an invention in 152153 PCT Contracting States.”).
219
Id.
220 See When Will the Unitary Patent System Start? EUROPEAN PATENT OFFICE,
(last visited on Feb. 26, 2020), https://www.epo.org/law-practice/unitary/
unitary-patent/start.html [https://perma.cc/N3TA-C7NQ] (“The start of the new
system is currently expected for the end of 2020.”).
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effective centralized recordation system is particularly relevant to
the newly proposed unitary patent system. Again, the additions
would be easy: just a couple more questions to answer when filing
with the EPO.
Overall, filling out basic chain-of-title information at the same
time as the filling of the PCT application or EPO unitary patent
application would help prevent simple mistakes from happening, or
lapsing in memories or written records. While each country will
continue to have their own unique approach to initial patent
entitlement, mechanisms for patent assignments, and decisions
whether to provide additional monetary payments to employees,
each country can use a common system of notice. This system of
notice is one that is already used across the world in secured
transactions laws to increase transparency and predictability, and,
thereby, certainty, to all parties within the global patenting
marketplace.
CONCLUSION
Employee inventions are an important source of innovation
around the world, yet the assignment of these inventions are also a
source of transactional inefficiency and increased patent litigation.
By itself, conveying legal title of a patent is not difficult, yet it
becomes more complex when the rules of patent assignments
regarding patent priority are different from country to country.
There is no worldwide, uniform approach for parties to follow when
assigning patents in order to avoid future patent priority challenges.
This creates opportunity for parties to capitalize on drafting errors,
omissions in a complex merger or acquisition, or simply
disorganized corporation record-keeping systems.
More so than ever before, innovation requires a multinational
approach, one where global partners have accurate information
about one another, both to help assess the competition and to decide
when a partnership is worth building. This Article has argued that
creating a centralized recordation system, one based upon alreadyexisting secured transactions databases, would help reduce the
amount of opportunism and user errors by promoting transparency
and predictability, while also providing an easy way to ensure that
information regarding priority and chain of title is valued and
encouraged. Though no worldwide centralized system currently
exists, there are groups, such as the AIPPI and IP5, that have
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expressed an interest in the connection of secured transactions law
and intellectual property law. And, finally, even if no centralized
databased is built, there are also opportunities to build disclosures
into already-existing multi-country patenting processes in Europe.
This is particularly true with the unitary patent system that is
scheduled to launch in Europe at the end of this year.
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